Statistical Analysis Plan

NCT Number: NCT03710486

Title: Vedolizumab and anti-TNFs Outcomes in Real-World Biologic Ulcerative Colitis and Crohn's Disease Patients (EVOLVE) – IBERIA

Study Number: Vedolizumab-5047

Document Version and Date: 6.0, 17FEB2022

Certain information within this document has been redacted (ie, specific content is masked irreversibly from view) to protect either personally identifiable information or company confidential information.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

STATISTICAL ANALYSIS PLAN

Trial Name:	EVOLVE study
Trial Title:	Vedolizumab and anti-TNFs Outcomes in Real-World Biologic Ulcerative Colitis and Crohn's Disease Patients (EVOLVE) – IBERIA
Protocol No.:	TAK-VEZ-2018-01
Sponsor:	Takeda Farmacéutica España SA

Reference to version and date of protocol and SAP on which report is based	
Protocol version:	2.0
Protocol date:	23MAY2019
SAP Version:	NA
SAP date:	NA

Date:	17FEB2022
Version:	6.0

Performed by:	**Performed for:**

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

1. Approvals (signatures)

The signatures on this page indicate the review and approval of the statistical analysis plan of the EVOLVE study.

BioClever: [redacted]

(Signature) [redacted] Date: 17/2/2022

Sponsor: [redacted]

(Signature) [redacted] Date: 18/2/2022

Sponsor: [redacted]

(Signature) [redacted] Date: 18/2/2022

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Index

1. Approvals (signatures) 2
2. Distribution List 14
3. Document Version History 14
4. Study objectives 15
4.1 Primary objective 15
4.2 Secondary objectives 15
4.3 Exploratory Objectives 15
5. Overall study design 15
5.1 Study design 15
5.2 Sample size 16
5.3 Changes to the protocol 16
6. General statistical considerations 16
6.1 Study population 16
6.2 General issues 16
6.3 Presentation/Format of the results 17
6.4 Level of significance and multiplicity 17
6.5 Handling of dropouts and missing data 17
7. Description of the statistical analysis 17
7.1 Definitions of variables 17
7.2 Hypothesis and statistical methods 23
7.2.1 Univariate analysis. Descriptive statistics 23
7.2.2 Bivariate analysis 23
7.3 Demographic and baseline characteristics 24
7.4 Primary objective analysis 24
7.4.1 Descriptive analysis 24
7.4.2 Endpoint analysis 24
7.5 Analysis of secondary objectives 30
7.6 Exploratory Objectives 31
8. References 32

Property of Takeda. For Non-commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9. Results 33
9.1 Study population 33
9.2 Descriptive analysis 35
9.2.1 Groups description 35
9.2.2 By treatment 39
9.2.3 By treatment (CD patients) 60
9.2.4 By treatment line (CD-VDZ patients) 60
9.2.5 By treatment line (CD-Other Biologic Patients) 61
9.2.6 By treatment (UC patients) 61
9.2.7 By treatment line (UC-VDZ patients) 62
9.2.8 By treatment line (UC-Other Biologic Patients) 62
9.3 Primary Objective (Descriptive analysis) 63
9.3.1 Descriptive by treatment 63
9.3.2 By treatment (CD patients) 70
9.3.3 By treatment line (CD-VDZ patients) 70
9.3.4 By treatment line (CD-Other Biologic Patients) 71
9.3.5 By treatment (UC patients) 71
9.3.6 By treatment line (UC-VDZ patients) 72
9.3.7 By treatment line (UC-Other Biologic Patients) 72
9.4 Primary objective (Endpoint analysis) 73
9.4.1 PS-IPTW 73
9.4.2 Discontinuation 91
9.4.3 Time to treatment discontinuation 108
9.4.4 Duration of treatment 116
9.4.5 Intensification 124
9.4.6 Time to first intensification 141
9.4.7 Clinical response 148
9.4.8 Clinical remission 165
9.4.9 Endoscopic response at 52 weeks 166
9.4.10 Endoscopic remission at 52 weeks 167
9.4.11 Biochemical remission based on CRP 168
9.4.12 Biochemical remission based on fecal calprotectin 168

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.5 Secondary objectives 169

9.5.1 Describe the real world clinical effectiveness of VDZ vs. other biologics at least 12 months post-treatment initiation (in a subgroup of patients with adequate follow-up available) 169

9.5.2 Quantify healthcare resource utilization including the rates of healthcare professional (HCP) and emergency department (ED) visits, hospitalizations and Inflammatory Bowel Disease (IBD) related surgical procedures 170

9.5.3 Identify predictors of response to VDZ 185

9.5.4 Describe treatment patterns, clinical effectiveness and safety events for at least the induction phase of the subsequent biologic regimen for patients who discontinue index treatment in the VDZ cohort and initiate a second -line biologic within 6 months post-index treatment discontinuation 186

9.5.5 Describe the safety events occurring post biologic treatment initiation (VDZ or other biologics) 191

Table Index

Table 1.1.1 Patients recruited, valid and excluded 33

Table 1.1.2 Follow-up 34

Table 2.1.1 Groups and subgroups 35

Table 2.2.1 Demographics 39

Table 2.2.2 Disease Characteristics – CD patients 41

Table 2.2.3 Disease Activity – CD patients 43

Table 2.2.4 Disease Characteristics – UC patients 47

Table 2.2.5 Disease Activity – UC patients 47

Table 2.2.6 Diagnostic imaging 50

Table 2.2.7 Laboratory determinations 51

Table 2.2.8 Extra Intestinal Manifestations 52

Table 2.2.9 Comorbid medical conditions 54

Table 2.2.10 Biologic treatment pre index treatment 56

Table 2.2.11 Non-biologic treatment 58

Table 2.2.12 End of study 59

Table 2.3.1 Demographics (CD patients) 60

Table 2.4.1 Demographics (CD-VDZ patients) 60

Table 2.5.1 Demographics (CD-Other Biologic patients) 61

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 2.6.1 Demographics (UC patients) 61

Table 2.7.1 Demographics (UC-VDZ patients) 62

Table 2.8.1 Demographics (UC-Other Biologic patients) 62

Table 3.1.1 Biologic index treatment I 63

Table 3.1.2 Biologic index treatment II 65

Table 3.1.3 Follow-up 68

Table 3.1.4 Concomitant treatment 69

Table 3.2.1 Biologic index treatment I (CD patients) 70

Table 3.3.1 Biologic index treatment I (CD-VDZ patients) 70

Table 3.4.1 Biologic index treatment I (CD-Other Biologic patients) 71

Table 3.5.1 Biologic index treatment I (UC patients) 71

Table 3.6.1 Biologic index treatment I (UC-VDZ patients) 72

Table 3.7.1 Biologic index treatment I (UC-Other Biologic patients) 72

Table 4.1.1 Descriptive analysis pre and post PS-IPTW (CD patients) 73

Table 4.1.2 Descriptive analysis pre and post PS-IPTW (UC patients) 76

Table 4.1.3 Descriptive analysis pre and post PS-IPTW (CD patients – First line) 79

Table 4.1.4 Descriptive analysis pre and post PS-IPTW (UC patients – First line) 82

Table 4.1.5 Descriptive analysis pre and post PS-IPTW (CD patients – Second line) ... 85

Table 4.1.6 Descriptive analysis pre and post PS-IPTW (UC patients – Second line) ... 88

Table 4.2.1 Discontinuation 91

Table 4.2.2 CD patients with VDZ – Discontinuation Logistic regression model (p-values) 100

Table 4.2.3 CD patients with VDZ – Discontinuation Logistic regression model (estimated OR) 101

Table 4.2.4 UC patients with VDZ – Discontinuation Logistic regression model (p-values) 102

Table 4.2.5 UC patients with VDZ – Discontinuation Logistic regression model (estimated OR) 103

Table 4.2.6 CD patients with Other Biologic – Discontinuation Logistic regression model (p-values) 104

Table 4.2.7 CD patients with Other Biologic – Discontinuation Logistic regression model (estimated OR) 105

Table 4.2.8 UC patients with Other Biologic – Discontinuation Logistic regression model (p-values) 106

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.2.9 UC patients with Other Biologic – Discontinuation Logistic regression model (estimated OR) 107

Table 4.3.1 Time to treatment discontinuation (Months) 108

Table 4.4.1 Duration of treatment (Months) 116

Table 4.5.1 Patients with one intensification or more (%) 124

Table 4.5.2 CD patients with VDZ – One intensification or more Logistic regression model (p-values) 133

Table 4.5.3 CD patients with VDZ – One intensification or more Logistic regression model (estimated OR) 134

Table 4.5.4 UC patients with VDZ – One intensification or more Logistic regression model (p-values) 135

Table 4.5.5 UC patients with VDZ – One intensification or more Logistic regression model (estimated OR) 136

Table 4.5.6 CD patients with Other Biologic – One intensification or more Logistic regression model (p-values) 137

Table 4.5.7 CD patients with Other Biologic – One intensification or more Logistic regression model (estimated OR) 138

Table 4.5.8 UC patients with Other Biologic – One intensification or more Logistic regression model (p-values) 139

Table 4.5.9 UC patients with Other Biologic – One intensification or more Logistic regression model (estimated OR) 140

Table 4.6.1 Time to first intensification (Months) 141

Table 4.7.1 Clinical response at 14 weeks 148

Table 4.7.2 Clinical response at 52 weeks 156

Table 4.7.3 CD patients with VDZ – Clinical response at 52 weeks Logistic regression model (p-values) 157

Table 4.7.4 CD patients with VDZ – Clinical response at 52 weeks Logistic regression model (estimated OR) 158

Table 4.7.5 UC patients with VDZ – Clinical response at 52 weeks Logistic regression model (p-values) 159

Table 4.7.6 UC patients with VDZ – Clinical response at 52 weeks Logistic regression model (estimated OR) 160

Table 4.7.7 CD patients with Other Biologic – Clinical response at 52 weeks Logistic regression model (p-values) 161

Table 4.7.8 CD patients with Other Biologic – Clinical response at 52 weeks Logistic regression model (estimated OR) 162

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.7.9 UC patients with Other Biologic – Clinical response at 52 weeks Logistic regression model (p-values) 163

Table 4.7.10 UC patients with Other Biologic – Clinical response at 52 weeks Logistic regression model (estimated OR) 164

Table 4.8.1 Clinical remission at 14 weeks 165

Table 4.8.2 Clinical remission at 52 weeks 165

Table 4.8.3 CD patients with VDZ – Clinical remission at 52 weeks Logistic regression model (p-values) 165

Table 4.8.4 CD patients with VDZ – Clinical remission at 52 weeks Logistic regression model (estimated OR) 165

Table 4.8.5 UC patients with VDZ – Clinical remission at 52 weeks Logistic regression model (p-values) 165

Table 4.8.6 UC patients with VDZ – Clinical remission at 52 weeks Logistic regression model (estimated OR) 165

Table 4.8.7 CD patients with Other Biologic – Clinical remission at 52 weeks Logistic regression model (p-values) 165

Table 4.8.8 CD patients with Other Biologic – Clinical remission at 52 weeks Logistic regression model (estimated OR) 165

Table 4.8.9 UC patients with Other Biologic – Clinical remission at 52 weeks Logistic regression model (p-values) 165

Table 4.8.10 UC patients with Other Biologic – Clinical remission at 52 weeks Logistic regression model (estimated OR) 165

Table 4.9.1 Endoscopic response at 52 weeks 166

Table 4.9.2 CD patients with VDZ – Endoscopic response at 52 weeks Logistic regression model (p-values) 166

Table 4.9.3 CD patients with VDZ – Endoscopic response at 52 weeks Logistic regression model (estimated OR) 166

Table 4.9.4 UC patients with VDZ – Endoscopic response at 52 weeks Logistic regression model (p-values) 166

Table 4.9.5 UC patients with VDZ – Endoscopic response at 52 weeks Logistic regression model (estimated OR) 166

Table 4.9.6 CD patients with Other Biologic – Endoscopic response at 52 weeks Logistic regression model (p-values) 166

Table 4.9.7 CD patients with Other Biologic – Endoscopic response at 52 weeks Logistic regression model (estimated OR) 166

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.9.8 UC patients with Other Biologic – Endoscopic response at 52 weeks Logistic regression model (p-values) 166

Table 4.9.9 UC patients with Other Biologic – Endoscopic response at 52 weeks Logistic regression model (estimated OR) 166

Table 4.10.1 Endoscopic remission at 52 weeks 167

Table 4.11.1 Biochemical remission based on CRP at 14 weeks 168

Table 4.11.2 Biochemical remission based on CRP at 52 weeks 168

Table 4.12.1 Biochemical remission based on fecal calprotectin at 14 weeks 168

Table 4.12.2 Biochemical remission based on fecal calprotectin at 52 weeks 168

Table 5.2.1 Health resource utilization – CD with VDZ patients 170

Table 5.2.2 Health resource utilization related to the pathology – CD with VDZ patients 173

Table 5.2.3 Health resource utilization – CD patients with other biologic 177

Table 5.2.4 Health resource utilization related to the pathology – CD patients with other biologic 180

Table 5.2.1 Health resource utilization – UC patients with VDZ 184

Table 5.2.2 Health resource utilization related to the pathology – UC patients with VDZ 184

Table 5.2.3 Health resource utilization – CD patients with other biologic 184

Table 5.2.4 Health resource utilization related to the pathology – UC patients with other biologic 184

Table 5.4.1 Patients who discontinue index treatment in the VDZ cohort and initiate a second-line biologic within 6 months post-index treatment discontinuation 186

Table 5.4.1 New treatment 187

Table 5.4.2 Posology (mg) by treatment 188

Table 5.4.1 New treatment – Response and remission 14 weeks 189

Table 5.4.2 New treatment – Adverse Events 190

Table 5.5.1 Adverse Events 191

Table 5.5.2 Adverse event (incidence) 194

Table 5.5.3 Serious Adverse event (incidence) 195

Table 5.5.4 Related with treatmetn Adverse Event (incidence) 195

Table 5.5.5 Related with treatment Serious Adverse Event (incidence) 195

Table 5.5.6 Adverse event - Infections, serious infections and malignancies (incidence) 195

Table 5.5.1 Adverse event (incidence rate) 196

Table 5.5.2 Serious Adverse event (incidence rate) 196

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.5.3 Related with index date Adverse Event (incidence rate) 197

Table 5.5.4 Related with index date Serious Adverse Event (incidence rate) 197

Table 5.5.5 Adverse event - Infections, serious infections and malignancies (incidence rate) 197

Table 5.5.6 Adverse Events I – CD patients with VDZ 198

Table 5.5.7 Adverse Events II – CD patients with VDZ 199

Table 5.5.8 Adverse Events III – CD patients with VDZ 200

Table 5.5.9 Adverse Events I – CD patients with Other Biologic 201

Table 5.5.10 Adverse Events II – CD patients with Other Biologic 202

Table 5.5.11 Adverse Events III – CD patients with Other Biologic 203

Table 5.5.12 Adverse Events I – UC patients with VDZ 204

Table 5.5.13 Adverse Events II – UC patients with VDZ 204

Table 5.5.14 Adverse Events III – UC patients with VDZ 204

Table 5.5.15 Adverse Events I – UC patients with Other Biologic 204

Table 5.5.16 Adverse Events II – UC patients with Other Biologic 204

Table 5.5.17 Adverse Events III – UC patients with Other Biologic 204

Figure index

Figure 4.1.1 Density Plot – pre PS-IPTW (CD) 75

Figure 4.1.2 Density Plot – Post-IPTW (CD) 75

Figure 4.1.3 Love Plot (CD) 75

Figure 4.1.4 Box Plots (CD) 75

Figure 4.1.5 Density Plot – pre PS-IPTW (UC) 78

Figure 4.1.6 Density Plot – Post-IPTW (UC) 78

Figure 4.1.7 Love Plot (UC) 78

Figure 4.1.8 Box Plots (UC) 78

Figure 4.1.9 Density Plot – pre PS-IPTW (CD – First line) 81

Figure 4.1.10 Density Plot – Post-IPTW (CD – First line) 81

Figure 4.1.11 Love Plot (CD – First line) 81

Figure 4.1.12 Box Plots (CD – First line) 81

Figure 4.1.13 Density Plot – pre PS-IPTW (UC – First line) 84

Figure 4.1.14 Density Plot – Post-IPTW (UC – First line) 84

Property of Takeda. For Non-commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Figure 4.1.15 Love Plot (UC – First line)..... 84
Figure 4.1.16 Box Plots (UC – First line) 84
Figure 4.1.17 Density Plot – pre PS-IPTW (CD – Second line) 87
Figure 4.1.18 Density Plot – Post-IPTW (CD – Second line)..... 87
Figure 4.1.19 Love Plot (CD – Second line)..... 87
Figure 4.1.20 Box Plots (CD – Second line) 87
Figure 4.1.21 Density Plot – pre PS-IPTW (UC – Second line) 90
Figure 4.1.22 Density Plot – Post-IPTW (UC – Second line)..... 90
Figure 4.1.23 Love Plot (UC – Second line)..... 90
Figure 4.1.24 Box Plots (UC – Second line) 90
Figure 4.4.1 Duration of treatment (months) 123

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

ABBREVIATIONS AND DEFINITIONS

5-ASA	5-aminosalicylic acid
AE	Adverse Event
AIDS	Acquired immune deficiency syndrome
ALT	Alanine transaminase
ANOVA	Analysis of variance
AST	Aspartate transaminase
BMI	Body Mass Index
BUN	Blood urea nitrogen
CD	Crohn's disease
CHF	Congestive heart failure
CI	Confidence interval
CKD	Chronic kidney disease
CPPD	Calcium pyrophosphate dihydrate
CVA	Cerebrovascular accident
ED	Emergency Department
GPP	Good Pharmacoepidemiology Practices
HCP	Healthcare professional
HBI	Harvey-Bradshaw Index
IBD	Inflammatory bowel disease
PS-IPTW	Inverse Probability Treatment Weighting
MedDRA	Medical Dictionary for regulatory activities
MRI	Magnetic resonance imaging
NA	Not applied
OR	Odds Ratio
RR	Relative Risk
PCR	C Reactive Protein
PSC	Primary sclerosing colangitis
PT	Preferred Term
Q1/Q3	First and third quartile
SES-CD	Simple endoscopic score for Crohn’s disease
SAS	Statistical Analysis Software
SD	Standard Deviation
SOC	System Organ Class
TIA	Transient ischemic attack
UC	Ulcerative colitis

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

VDZ	Vedolizumab
VSG	Erythrocyte Sedimentation Rate

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

2. Distribution List

Name	Function / Role	Office/Sponsor
[redacted]	Sponsor	Takeda
	Sponsor	Takeda
	Sponsor	Takeda
	Sponsor	Takeda
	Sponsor	Takeda

3. Document Version History

Version	Effective Date	Significant Changes
1.0	27MAY2020	New endpoints and Propensity score PS-IPTW methodology.
2.0	15DEC2020	A logistic regression with Other Biologic patients, all Kaplan-Meier's graphs and other minor changes.
3.0	13JAN2021	Additional covariates for PS-IPTW. Boxplots for analysis of the distribution of covariates after PS-IPTW. Other minor changes.
4.0	24JAN2021	Removed comments.
5.0	03FEB2022	Correct minor errors.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

4. Study objectives

4.1 Primary objective

- Describe treatment patterns associated with first-line and second line biologic use (VDZ or other biologic: infliximab, adalimumab, or golimumab, [UC only]) (e.g., dose escalation, treatment discontinuation, and switching).
- Describe the real-world clinical effectiveness of the use (first-line and second line) VDZ vs. other biologics at least 6 months post-treatment initiation.

4.2 Secondary objectives

- Characterize patients treated with VDZ or other biologics (infliximab, adalimumab, or golimumab [UC only]) as first and second line biologic therapy in terms of demographics, medical, and treatment histories.
- Describe the real world clinical effectiveness of VDZ vs. other biologics at least 12 months post-treatment initiation (in a subgroup of patients with adequate follow-up available).
- Describe the safety events occurring post biologic treatment initiation (VDZ or other biologics).
- Quantify healthcare resource utilization including the rates of healthcare professional (HCP) and emergency department (ED) visits, hospitalizations and Inflammatory Bowel Disease (IBD) related surgical procedures.

[redacted]

5. Overall study design

5.1 Study design

This study is a 'non-interventional study' as defined in Directive 2001/20/EC and will follow the guidelines for GPP.

This means that:

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- The assignment of a subject to a particular therapeutic strategy is not decided in advance by the study protocol but falls within current practice.
- No additional diagnostic or monitoring procedures shall be applied to the subjects.
- Epidemiological methods shall be used for the analysis of collected data.

The study is an ethics-approved, designed as a multicentre, retrospective cohort study of the medical charts of patients who were diagnosed with CD or UC and who initiated first- or second-line biologic treatment with VDZ or another biologic (infliximab, adalimumab, or golimumab [UC only]) (index event) during the eligibility period: January 2017 to date of site initiation.

The target sample size is approximately 400 patients (200 patients per treatment cohort: 1) VDZ and 2) other biologics. It is estimated that these patients will be included from across ~25 sites (20 in Spain and 5 in Portugal), resulting on average in ~8 patients per treatment cohort/site. The medical charts of patients with UC or CD who initiated first-line or second-line biologic treatment with VDZ or another biologic (infliximab, adalimumab, or golimumab [UC only]) during the eligibility period will be identified for potential enrolment.

5.2 Sample size

The primary objective of the study is descriptive. Therefore, the sample size calculation is based in the precision of a confidence interval estimation of a proportion. The study will recruit two types of patients; the distribution will be 1:1. Both groups will be evaluated separately in consequence we calculated a sample size calculation for each group.

We assumed the scenario of maximum indetermination (i.e., an expected proportion of 50%). To obtain a confidence interval of 95% of this proportion with a precision of 7.5% is necessary to recruit 171 patients. We expect a 10% of non-valid data so we will recruit 200 patients per group (400 patients in total).

- 200 patients treated with a first-line or second-line VDZ.
- 200 patients treated with first-line or second-line of other biologics (infliximab, adalimumab, golimumab).

5.3 Changes to the protocol

NA.

6. General statistical considerations

6.1 Study population

Valid sample: Patients that meet all the inclusion criteria and none of exclusion.

6.2 General issues

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

The content of the clinical database will be transferred to SAS® datasets for statistical analysis. All statistical analyses will be performed using the statistical package SAS® system version 9.4 or posterior.

In section 9 the tables of the statistical analysis are shown.

6.3 Presentation/Format of the results

In general, for the continuous variables, the description of the mean, median and standard deviation is presented with an additional decimal and for the minimum and maximum values it is presented with the same level of accuracy as the raw data.

For the categorical variables, the percentages are presented with a decimal figure.

6.4 Level of significance and multiplicity

The level of significance that will be adopted for all tests has been 0.05 bilateral.

No adjustment will be made for multiple comparisons or corrections for multiplicity.

6.5 Handling of dropouts and missing data

Missing data of PS-IPTW model variables will be imputed by means of PROC MI and FCS option (SAS software version 9.4 or posterior). Multiple imputation will include 25 datasets.

7. Description of the statistical analysis

7.1 Definitions of variables

Index date: Date of the initiation of treatment (VDZ or other biologic)

- Time of follow-up (months):

(Date of last time alive/Date of death – index date)/30.4375

- Patients with follow-up of 12 months or more:

Patients with “Time of follow-up” equal or greater than 12: Yes

Patients without “Time of follow-up” equal or greater than 12: No

- Time between index date and assessment (weeks):

(Date of assessment – Index date)/7

- Time between intensification and index date (months):

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

(Date of intensification – Date of index date)/30.4375

- Time between induction and maintenance (weeks):

(Date of maintenance initial – date of induction initial)/7

- Time between index treatment and new treatment (months):

(Date of new treatment initial – Index date)/30.4375

- Number of visits (global and by type):

Sum of visits and sum of visit by type.

- AEs duration (days):

(Date of resolution – Start of onset)+1

- Assessment for clinical response and remision:
    - Select all assesments posterior to index date and with HBI value/Partial Mayo (CD or UC patients) or physician statuts other than missing, NA or Unknown.
    - Select assesments inside time window 10-18 weeks for 14 weeks assessment and 46-58 weeks for 52 weeks assessment. For each patient the nearest assessment to 14 and 52 will be seleceted. In case of two evaluation at the same distance from 14 or 52 the latests assessment will be selected.
    - Patients without assessment inside time window:
        - If there is a discontinuation registred before 14 or 52 we will impute a "No" clinical remission and clinical response for 14 or 52 weeks assessment.
        - If there is not a discontinuation:
            - Select all assessments below time window (<10 weeks or <46 weeks). For each patient the latest assessment will be selected.
- Assessment for clinical response and remission (New treatment):

The same methodology below for 14 weeks but using date of start of new treatment instead of index date.

- Clinical response (CD patients):
    - HBI score registered or calculated (if both are available used that registered in the clinical chart):
        - Yes:

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- HBI score equal or less than 4: Clinical response = Yes.
- HBI score at index date equal or greater than 3:
  - Reduction (difference from index date) equal or greater than 3: Clinical response = Yes.
  - Reduction (difference from index date) less than 3: Clinical response = No
- Other case: Physician assessment registered.

▪ No: Physician assessment registered

○ Physician assessment registered:

▪ Yes

- Remission or Partial remission: Clinical response = Yes
- Not in remission: Clinical response =No
- Unknown or NA: Missing

▪ No: Clinical response = Missing

- Clinical remission (CD patients):
  - HBI score registered or calculated (if both are available used that registered in the clinical chart):
    - Yes:
      - HBI score equal or less than 4: Clinical remission = Yes.
      - HBI score greater than 4: Clinical remission = No
    - No: Physician assessment registered.
  - Physician assessment registered:
    - Yes
      - Remission: Clinical remission = Yes
      - Partial remission or not in remission Clinical remission =No
      - Unknown or NA: Missing
    - No: Clinical remission = Missing

- Clinical response (UC patients):
  - Partial Mayo score registered or calculated:
    - Yes:
      - Partial Mayo score less than 4: Clinical response = Yes.
      - Partial Mayo score at index date equal or greater than 2:
        - Reduction (difference from index date) equal or greater than 2: Clinical response = Yes.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- Reduction (difference from index date) less than 2: Clinical response = No
- Other case: Physician assessment registered

- No: Physician assessment registered

- Physician assessment registered:
  - Yes
    - Remission or Partial remission: Clinical response = Yes
    - Not in remission: Clinical response =No
    - Unknown or NA: Missing
  - No: Clinical response = Missing

- Clinical remission (UC patients):
  - Partial Mayo score registered or calculated:
    - Yes:
      - Partial Mayo score less than 2: Clinical remission = Yes.
      - Partial Mayo score equal or greater than 2: Clinical remission = No
    - No: Physician assessment registered
  - Physician assessment registered:
    - Yes
      - Remission: Clinical remission = Yes
      - Partial remission or not in remission: Clinical remission =No
      - Unknown or NA: Missing
    - No: Clinical remission = Missing

- Assessment for endoscopic response and remision:
  - Select all assesments posterior to index date and with SES-CD (only Cd patients) or endoscopic statuts other than missing, NA or Unknown.
  - Select assesments inside time window 28-76 weeks for 52 weeks assessment. For each patient the nearest assessment to 52 will be seleceted. In case of two evaluation at the same distance from 52 the latests assessment will be selected.
  - Patients without assessment inside time window: Select all assessments below time window <28 weeks. For each patient the latest assessment will be selected

- Endoscopic response at 52 weeks (CD and UC patients):
  - Endoscopy:

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- SES-CD score registered (only CD patients):
  - Yes
    - SES-CD score equal or less than 2: Endoscopic response = Yes.
    - SES-CD greater than 2 and SES-CD at index date equal 0: Endoscopic response = No.
    - In other case:
      - SES-CD at index date greater than 0 relative difference will be calculated {100*(Index date – 52 weeks assessment)/Index date} :
        - Greater or equal 50%: Endoscopic response=Yes
        - Less than 50: Endoscopic response=No
      - Other case: Endescopic response=Missing
  - No: Physician assessment
- Physician assessment
  - Remission or Partial remission: Endoscopic response = Yes
  - Not in remission: Endoscopic response =No

- <u>Endoscopic remission at 52 weeks (CD and UC patients):</u>
  - Endoscopy:
    - SES-CD score registered (only CD patients):
      - Yes
        - SES-CD score equal or less than 2: Endoscopic remission = Yes.
        - SES-CD score greater than 2: Endoscopic remission = No
      - No: Physician assessment
    - Physician assessment:
      - Remission: Endoscopic remission = Yes
      - Partial remission or not in remission: Endoscopic remission =No

- <u>Assessment for bioquimic remission based on CRP/fecal calcoprotectin at 14 and 52 weeks:</u>
  - Select all assesments posterior to index date and with CRP/fecal calcoprotectin.
  - Select assesments inside time window >0-38 weeks for 14 weeks assessment and 28-76 weeks for 52 weeks assessment. For each patient the nearest assessment to 14 and 52 will be seleceted. In case of two evaluation at the same distance from 14 or 52 the latests assessment will be selected.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- Biochemical remission based on CRP (CD and UC patients):
    - CRP (mg/L):
        - <5: Biochemical remission = Yes
        - >=5: Biochemical remission =No

- Biochemical remission based on fecal calprotectin (CD and UC patients):
    - Fecal calcoprotein (µg/g):
        - <250: Biochemical remission = Yes
        - >=250: Biochemical remission =No

- Time to discontinuation (months):
    - Is the treatment ongoing? = No
        - (date of discontinuation – index date)/30.4375
    - Is the treatment ongoing? = Yes
        - Censured time: (date of the last assessment – index date)/30.4375

- Time to first intensification (months):
    - Is the treatment ongoing? = No
        - Has there been intensification? = Yes
            - (date of the first intensification – index date)/30.4375
        - Has there been intensification? = No
            - Censured time: (date of discontinuation – index date)/30.4375
    - Is the treatment ongoing? = Yes
        - Has there been intensification? = Yes
            - (date of the first intensification – index date)/30.4375
        - Has there been intensification? = No
            - Censured time: (date of the last assessment – index date)/30.4375

- Perianal disease at diagnosis:
    - Fistulas at diagnosis=Yes and type=anal or rectovaginal -> Yes
    - Disease behaviour = Anal (CD patients) -> Yes
    - Other case -> No

- Previous abdominal surgeries:

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- Yes if Health resource utilization includes:
  - Any resection
  - Any resection with ostomy
  - Any resection with reservoir
  - Any stricturoplasty

- Reason end of first line:
  - Primary failure: “PNR: Without primary response”
  - Secondary failure: “SLR: Lost of response”
  - Safety: “AE: Adverse Event”
  - Other:
    - “PR: Partial response”
    - “Remission”
    - “Other”
  - Missing: “Unknown”

7.2 Hypothesis and statistical methods

7.2.1 Univariate analysis. Descriptive statistics

Descriptive analysis of the collected variables will be carried out. Depending on the variable nature will be presented:

- Categorical variables will be summarized by frequencies and percentages.
- Continuous variables will be summarized by means of central tendency and dispersion measures: mean, standard deviation, median, 25% and 75% (Q1 and Q3) percentiles and extreme values (minimum and maximum).

7.2.2 Bivariate analysis

When it is of interest to answer the study objectives, the relationship between variables will be evaluated:

- For two categorical variables, contingency tables with the frequency in each category and the percentage by columns will be presented. To evaluate the possible association Chi-square tests or Fisher's exact test will be performed and the resulting p-value will be presented.
- For a numerical variable with a categorical, descriptive statistics will be presented by groups. To evaluate the possible association, T-Test, ANOVA or Wilcoxon or Kruskal-Wallis nonparametric tests will be performed, as well as their resulting p-value.

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- To evaluate the relationship between two numerical variables, the Pearson or Spearman correlation will be presented, as well as its resulting p-value.

7.3 Demographic and baseline characteristics

The description of the data will be presented by means of the methods described in section 7.2.

7.4 Primary objective analysis

7.4.1 Descriptive analysis

A description analysis of the treatment patterns of biologic treatment observed by:

- VDZ/Other
- CD patients:
    - VDZ/Other
    - VDZ:
        - First line / Second line
    - Other:
        - First line / Second line
- UC patients:
    - VDZ/Other
    - VDZ:
        - First line / Second line
    - Other:
        - First line / Second line

7.4.2 Endpoint analysis

Propensity scores inverse probability treatment weighting (PS-IPTW) will be used to ensure comparability between treatment groups (VDZ vs. Other biologic). 5 propensity scores will be estimated:

- CD patients
- UC patients
- CD with 1st line treatment
- UC with 1st line treatment
- CD with 2nd line treatment
- UC with 2nd line treatment

A logistic regression with treatment group as a response will be adjusted to estimate PS-IPTW, the model will include:

- Age at index date (years)

Property of Takeda. For Non-commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- Sex
- Disease duration (time between first ever CD/UC diagnosis and index data (years))
- Smoking status at index date
- HBI score / Mayo score
- Perianal disease at diagnosis or index date (only CD patients)
- Previous abdominal surgeries
- Previous perianal surgeries
- Disease location
- Disease behaviour (only CD patients)
- Biologic treatment line (only with PS-IPTW for CD and UC patients)
- Any Corticosteroids treatment administered within the 6 months prior the index date
- Any Immunomodulators treatment administered within the 6 months prior the index date
- Logarithm of PCR (mg/L)
- Logarithm of Fecal calprotectin (mg/Kg)
- The patient has had extra intestinal manifestation within the 6 months prior the index date?
- Reason for discontinuation 1st line treatment (only for CD/UC 2nd line treatment patients)
    - Reasons for discontinuation will be pooled in the following way:
        - Primary failure
        - Secondary failure
        - Safety

The missing data of all variables will be imputed by using a multiple imputation method, see section 6.5.

A description of the variables without and with each PS-IPTW will be presented. A graphic with standardized means after and before each PS-IPTW (Love plot) will be presented. A density plot will be presented afet and before each PS-IPTW.

The distribution of each of the quantitative covariates included in the model after each PS-IPTW will be represented with boxplots.

List of endpoints:

- Discontinuation. Percentage of patients with discontinuation. Logistic regression will be used.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- Time to discontinuation. Median, p25 and p75 of time to discontinuation. Kaplan Meier and Log-Rank test will be used.
- Duration of treatment. Median, p25 and p75 of duration of treatment. Kaplan Meier and Log-Rank test will be used.
- Intensification. Percentage of patients with one or more intensification. Logistic regression will be used.
- Time to intensification. Median, p25 and p75 of time to discontinuation. Kaplan Meier and Log-Rank test will be used.
- Clinical response. Percentage of patients with clinical response. It will be evaluated at 14/52 weeks after index date. Logistic regression will be used.
- Clinical remission. Percentage of patients with clinical remission. It will be evaluated at 14/52 weeks after index date. Logistic regression will be used.
- Endoscopic response at 52 weeks. Percentage of patients with clinical response. Logistic regression will be used.
- Endoscopic remission at 52 weeks. Percentage of patients with clinical remission. Logistic regression will be used.
- Biochemical remission based on CPR. Percentage of patients with clinical remission. It will be evaluated at 14/52 weeks after index date. Logistic regression will be used.
- Biochemical remission based on fecal calcoprotein. Percentage of patients with clinical remission. It will be evaluated at 14/52 weeks after index date. Logistic regression will be used.

Each endpoint will be compare between:

- CD patients
    - VDZ – 1st line Vs. VDZ – 2nd line[1]
    - VDZ – Ileal Vs. VDZ – Colonic/Ileocolonic[1]
    - VDZ – Ileal – 1st line Vs. VDZ – Colonic/Ileocolonic – 1st line[1]
    - VDZ – Ileal – 2nd line Vs. VDZ – Colonic/Ileocolonic – 2nd line[1]
    - VDZ – Ileal – Intensification Vs. VDZ – Colonic/Ileocolonic – Intesification[1]
    - VDZ – Ileal – No Intensification Vs. VDZ – Colonic/Ileocolonic – No Intesification[1]
    - VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]
    - VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]
    - VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]
    - VDZ – Inflamatory Vs. VDZ – Stricturing/Penetrating[1]
    - VDZ – Inflamatory – 1st line Vs. VDZ – Stricturing/Penetrating – 1st line[1]

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- VDZ – Inflamatory – 2nd line Vs. VDZ – Stricturing/Penetrating – 2nd line[1]
- O.B. – 1st line Vs. O.B. – 2nd line[1]
- O.B. – Ileal Vs. O.B. – Colonic/Ileocolonic[1]
- O.B. – Ileal – 1st line Vs. O.B. – Colonic/Ileocolonic – 1st line[1]
- O.B. – Ileal – 2nd line Vs. O.B. – Colonic/Ileocolonic – 2nd line[1]
- O.B. – Ileal – Intensification Vs. O.B. – Colonic/Ileocolonic – Intesification[1]
- O.B. – Ileal – No Intensification Vs. O.B. – Colonic/Ileocolonic – No Intesification[1]
- O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]
- O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]
- O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]
- O.B. – Inflamatory Vs. O.B. – Stricturing/Penetrating[1]
- O.B. – Inflamatory – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line[1]
- O.B. – Inflamatory – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line[1]
- VDZ Vs. O.B.[2]
- VDZ – 1st line Vs. O.B. 1st line[3]
- VDZ – 2nd line Vs. O.B. 2nd line[4]
- VDZ – Colonic/Ileocolonic Vs. O.B. – Colonic/Ileocolonic[2]
- VDZ – Colonic/Ileocolonic – 1st line Vs. O.B. – Colonic/Ileocolonic 1st line[3]
- VDZ – Colonic/Ileocolonic – 2nd line Vs. O.B. – Colonic/Ileocolonic 2nd line[4]
- VDZ – Ileal Vs. O.B. – Ileal[2]
- VDZ – Ileal – 1st line Vs. O.B. – Ileal – 1st line[3]
- VDZ – Ileal – 2nd line Vs. O.B. – Ileal – 2nd line[4]
- VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[2]
- VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[3]
- VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[4]
- VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[2]
- VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[3]
- VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[4]
- VDZ – Inflamatory Vs. O.B. – Inflamatory [2]
- VDZ – Inflamatory – 1st line Vs. O.B. – Inflamatory – 1st line [3]

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- VDZ – Inflamatory – 2nd line Vs. O.B. – Inflamatory – 2nd line [4]
- VDZ Stricturing/Penetrating Vs. O.B. – Stricturing/Penetrating[2]
- VDZ Stricturing/Penetrating – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line [3]
- VDZ Stricturing/Penetrating – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line [4]

- UC
  - VDZ – 1st line Vs. VDZ – 2nd line[1]
  - VDZ – Extensive colitis Vs. VDZ – Proctitis/Left colitis[1]
  - VDZ – Extensive colitis – 1st line Vs. VDZ – Proctitis/Left colitis – 1st line[1]
  - VDZ – Extensive colitis – 2nd line Vs. VDZ – Proctitis/Left colitis – 2nd line[1]
  - VDZ – Extensive colitis – Intensification Vs. VDZ – Proctitis/Left colitis – Intesification[1]
  - VDZ – Extensive colitis – No Intensification Vs. VDZ – Proctitis/Left colitis – No Intesification[1]
  - VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]
  - VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]
  - VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]
  - O.B. – 1st line Vs. O.B. – 2nd line[1]
  - O.B. – Extensive colitis Vs. O.B. – Proctitis/Left colitis[1]
  - O.B. – Extensive colitis – 1st line Vs. O.B. – Proctitis/Left colitis – 1st line[1]
  - O.B. – Extensive colitis – 2nd line Vs. O.B. – Proctitis/Left colitis – 2nd line[1]
  - O.B. – Extensive colitis – Intensification Vs. O.B. – Proctitis/Left colitis – Intesification[1]
  - O.B. – Extensive colitis – No Intensification Vs. O.B. – Proctitis/Left colitis – No Intesification[1]
  - O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]
  - O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]
  - O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]
  - VDZ Vs. O.B.[5]
  - VDZ – 1st line Vs. O.B. 1st line[6]
  - VDZ – 2nd line Vs. O.B. 2nd line[7]
  - VDZ – Proctitis/Left colitis Vs. O.B. – Proctitis/Left colitis[5]

Property of Takeda: For Non Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- VDZ – Proctitis/Left colitis – 1st line Vs. O.B. – Proctitis/Left colitis 1st line[6]
- VDZ – Proctitis/Left colitis – 2nd line Vs. O.B. – Proctitis/Left colitis 2nd line[7]
- VDZ – Extensive colitis Vs. O.B. – Extensive colitis[5]
- VDZ – Extensive colitis – 1st line Vs. O.B. – Extensive colitis – 1st line[6]
- VDZ – Extensive colitis – 2nd line Vs. O.B. – Extensive colitis – 2nd line[7]
- VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[5]
- VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[6]
- VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[7]
- VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[5]
- VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[6]
- VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[7]

- [1]Data without PS-IPTW.
- [2]Data with PS-IPTW (CD).
- [3]Data with PS-IPTW (CD-1st line).
- [4]Data with PS-IPTW (CD-2nd line).
- [5]Data with PS-IPTW (UC).
- [6]Data with PS-IPTW (UC-1st line).
- [7]Data with PS-IPTW (UC-2nd line).

Per each endpoint a table with all the comparisons will be presented. The table will contain:

- Endpoint of each group of the comparison.
- Number of patients analysed per group of the comparison
- OR (only percentage endpoints)
- P-value.
- For each time to event comparison a figure with Kaplan-Meier's curves will presented.

Also a multivariate logistic regression will be performed for Discontinuation, One intensification or more, clinical response at 52 weeks and clinical remission at 52 weeks. The logistic regression will be performed separated by treatment group (VDZ and Other Biologic patients) and disease (CD and UC patients). Exploratory variables:

- Line of treatment
- Disease location
- Time between first ever CD/UC diagnosis and index date

Property of Takeda. For Non-commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- Disease behaviour (only CD patients)
- All interactions

The PROC MIANALYSE (SAS software 9.4 or posterior) will be used in all analyses.

7.5 Analysis of secondary objectives

- Characterize patients treated with VDZ or other biologics (infliximab, adalimumab, or golimumab [UC only]) as first and second line biologic therapy in terms of demographics, medical, and treatment histories.

View section 7.3.

- Describe the real world clinical effectiveness of VDZ vs. other biologics at least 12 months post-treatment initiation (in a subgroup of patients with adequate follow-up available).

Included in section 7.4.

- Describe the safety events occurring post biologic treatment initiation (VDZ or other biologics).

The incidence (%) and rate incidence (per 100 patient-year) of adverse events, serious adverse events, related with index treatment adverse events and related with index treatment serious adverse events, infections, serious infections and malignancies will be presented per each disease group (UC/DC).

The incidence and rate incidence will be compared between:

- CD patients
  - VDZ Vs. Other Biologic[1]
  - VDZ – 1st line Vs. Other Biologic 1st line[1]
  - VDZ – 2nd line Vs. Other Biologic 2nd line[2]
- UC patients
  - VDZ Vs. Other Biologic[3]
  - VDZ – 1st line Vs. Other Biologic 1st line[3]
  - VDZ – 2nd line Vs. Other Biologic 2nd line[4]

[1]Data with PS-IPTW (CD)

[2]Data with PS-IPTW (CD-2nd line)

[3]Data with PS-IPTW (UC)

[4]Data with PS-IPTW (UC-2nd line)

The incidence comparisons will be estimated by using a logistic regression.

The incidence rate comparisons will be estimated by using a Poisson regression.

Per each AA type and incidence/incidence rate a table with all the comparisons will be presented. The table will contain:

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

- Incidence/Incidence rate of each group of the comparison.
- OR (incidence) or RR (incidence rate)
- P-value.

Also a description analysis of the adverse events (one per each disease group CD/UC) will be presented by using the dictionary MedDRA (System Organ Class and Preferred term will be presented):

- Number and percentage of patients with an AE.
- Number of adverse events.
- Numbers of adverse events by:
  - Seriousness (Resulted in death / Was life-threatening / Required in patient hospitalization or prolongation of existing hospitalization / Resulted in persistent or significant disability or incapacity / Was a congenital anomaly or birth defect / Was an important medical event / None of the above)
  - Related to index drug (Yes / No)
  - Event Resolved (Yes (Duration) / No / Unknown)
  - Action taken with index drug (Treatment withdrawn / Dose reduced / Dose increased / Dose delayed / Dose not changed / Unknown / Not applicable)
  - Outcome (Recovered / Not recovered / Fatal / Recovering / Recovered with sequelae / Unknown)
  - Duration (days)

The PROC MIANALYSE (SAS software 9.4 or posterior) will be used in all analyses with PS-IPTW data.

- Quantify healthcare resource utilization including the rates of healthcare professional (HCP) and emergency department (ED) visits, hospitalizations and Inflammatory Bowel Disease (IBD) related surgical procedures.

Descriptive analysis of visits during the 12 months prior index date (index date included) and 12 months post-index date will be performed.

[redacted]

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

8. References

NA

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9. Results

9.1 Study population

Table 1.1.1 Patients recruited, valid and excluded

		Total patients recruited (n=xx)	Patients recruited with VDZ (n=xx)	Patients recruited with Other Biologic (n=xx)
Valid patients	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Excluded patients	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Reason of exclusion*:				
Patients without a diagnosis of moderate to severe UC or CD documented in the medical chart	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Patients that have not received any dose of VDZ or other biologic (infliximab, adalimumab, or golimumab [UC only]) during the eligibility period	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Patients younger than 18 years of age at the time of treatment initiation with VDZ or other biologic (index event)	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Patients that have not received the biologic treatment as first-line or second-line treatment for UC or CD	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Patients without a minimum of six months of follow up between index date and date of chart abstraction initiation	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Patients that received VDZ or another biologic as part of an interventional clinical trial ever in their lifetime (includes index treatment)	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Patients that initiated index treatment as combination therapy with two biologic agents	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Patients that the biologic was prescribed for the treatment of perianal disease	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Patients that have received a biologic prior to the index period for a disease other than inflammatory bowel disease	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		Total patients recruited (n=xx)	Patients recruited with VDZ (n=xx)	Patients recruited with Other Biologic (n=xx)
Patients with clinical record unavailable	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)

*The patients could present more than one reason.

Table 1.1.2 Follow-up

		Total patients (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Time of follow-up (months)	n	xx	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx	xx, xx
	Missing	xx	xx	xx
Patients with at least 12 months of follow-up				
Total no-missing	n	xx	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.2 Descriptive analysis

9.2.1 Groups description

Table 2.1.1 Groups and subgroups

		Total (n=xx)
Overall		
Treatment group		
Total no-missing	n	xx
VDZ	n (%)	xx (xx.x%)
Other biologic	n (%)	xx (xx.x%)
Missing	n	xx
Disease		
Total no-missing	n	xx
CD	n (%)	xx (xx.x%)
UC	n (%)	xx (xx.x%)
Missing	n	xx
Treatment line		
Total no-missing	n	xx
1st	n (%)	xx (xx.x%)
2nd	n (%)	xx (xx.x%)
Missing	n	xx
VDV		
Disease		
Total no-missing	n	xx
CD	n (%)	xx (xx.x%)
UC	n (%)	xx (xx.x%)
Missing	n	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		Total (n=xx)
Treatment line		
Total no-missing	n	xx
1st	n (%)	xx (xx.x%)
2nd	n (%)	xx (xx.x%)
Missing	n	xx
Other biologic		
Disease		
Total no-missing	n	xx
CD	n (%)	xx (xx.x%)
UC	n (%)	xx (xx.x%)
Missing	n	xx
Treatment line		
Total no-missing	n	xx
1st	n (%)	xx (xx.x%)
2nd	n (%)	xx (xx.x%)
Missing	n	xx
CD		
Treatment group		
Total no-missing	n	xx
VDZ	n (%)	xx (xx.x%)
Other biologic	n (%)	xx (xx.x%)
Missing	n	xx
Treatment line		
Total no-missing	n	xx
1st	n (%)	xx (xx.x%)

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		Total (n=xx)
2nd	n (%)	xx (xx.x%)
Missing	n	xx
UC		
Treatment group		
Total no-missing	n	xx
VDZ	n (%)	xx (xx.x%)
Other biologic	n (%)	xx (xx.x%)
Missing	n	xx
Treatment line		
Total no-missing	n	xx
1st	n (%)	xx (xx.x%)
2nd	n (%)	xx (xx.x%)
Missing	n	xx
CD-VDZ		
Treatment line		
Total no-missing	n	xx
1st	n (%)	xx (xx.x%)
2nd	n (%)	xx (xx.x%)
Missing	n	xx
CD-Other biologic		
Treatment line		
Total no-missing	n	xx
1st	n (%)	xx (xx.x%)
2nd	n (%)	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		Total (n=xx)
Missing	n	xx
UC-VDZ		
Treatment line		
Total no-missing	n	xx
1st	n (%)	xx (xx.x%)
2nd	n (%)	xx (xx.x%)
Missing	n	xx
UC-Other biologic		
Treatment line		
Total no-missing	n	xx
1st	n (%)	xx (xx.x%)
2nd	n (%)	xx (xx.x%)
Missing	n	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.2.2 By treatment

Table 2.2.1 Demographics

		VDZ (n=xx)	Other Biologic (n=xx)
Sex			
Total no-missing	n	xx	xx
Male	n (%)	xx (xx.x%)	xx (xx.x%)
Female	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Age at index date (years)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
BMI (Kg/m^2)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Smoking status at index treatment initiation			
Total no-missing	n	xx	xx
Never smoked	n (%)	xx (xx.x%)	xx (xx.x%)
Former smoker	n (%)	xx (xx.x%)	xx (xx.x%)
Current smoker	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
Number of years that the patient has smoked[1]	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Number of years that the patient has been smoked[2]	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Cigarettes per day[2]	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Work status at index date			
Total no-missing	n	xx	xx
Unemployed	n (%)	xx (xx.x%)	xx (xx.x%)
Retired	n (%)	xx (xx.x%)	xx (xx.x%)
Home maker	n (%)	xx (xx.x%)	xx (xx.x%)
Full-time employee	n (%)	xx (xx.x%)	xx (xx.x%)
Part-time employee	n (%)	xx (xx.x%)	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
Full-time student	n (%)	xx (xx.x%)	xx (xx.x%)
Part-time student	n (%)	xx (xx.x%)	xx (xx.x%)
Disability/sick leave	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Number of days the patient has been on sick leave within the 6 months prior to the index date	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx

[1] Former smoker patients.

[2] Current smoker patients.

Table 2.2.2 Disease Characteristics – CD patients

		VDZ (n=xx)	Other Biologic (n=xx)
Age at first ever CD diagnosis (years)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Location of intestinal involvement at diagnosis*			
Total no-missing	n	xx	xx
Ileal	n (%)	xx (xx.x%)	xx (xx.x%)
Colonic	n (%)	xx (xx.x%)	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
Upper GI tract	n (%)	xx (xx.x%)	xx (xx.x%)
Ileocolonic	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Type of disease behaviour at diagnosis*			
Total no-missing	n	xx	xx
Inflammatory	n (%)	xx (xx.x%)	xx (xx.x%)
Stricturing	n (%)	xx (xx.x%)	xx (xx.x%)
Penetrating	n (%)	xx (xx.x%)	xx (xx.x%)
Anal	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Active fistulas at diagnosis			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Type of active fistulas at diagnosis*[1]			
Total no-missing	n	xx	xx
Anal	n (%)	xx (xx.x%)	xx (xx.x%)
Rectovaginal	n (%)	xx (xx.x%)	xx (xx.x%)
Enterocutaneous	n (%)	xx (xx.x%)	xx (xx.x%)
Internal	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Number of fistulas	n	xx	xx

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx

[1] Patients with active fistulas.

* More than an answer possible.

Table 2.2.3 Disease Activity – CD patients

		VDZ (n=xx)	Other Biologic (n=xx)
Time between index date and assessment (months)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
HBI score registered in the medical chart?			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Can any subscale of HBI be extracted from medical chart?[1]			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
General well being[2]			
Total no-missing	n	xx	xx
Unknown	n (%)	xx (xx.x%)	xx (xx.x%)
Well or very well	n (%)	xx (xx.x%)	xx (xx.x%)
Slightly below par	n (%)	xx (xx.x%)	xx (xx.x%)
Poor	n (%)	xx (xx.x%)	xx (xx.x%)
Very poor	n (%)	xx (xx.x%)	xx (xx.x%)
Terrible	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Abdominal pain[2]			
Total no-missing	n	xx	xx
None	n (%)	xx (xx.x%)	xx (xx.x%)
Mild	n (%)	xx (xx.x%)	xx (xx.x%)
Moderate	n (%)	xx (xx.x%)	xx (xx.x%)
Severe	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Number of liquid or soft stools per day[2]	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Abdominal mass[2]			
Total no-missing	n	xx	xx

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
None	n (%)	xx (xx.x%)	xx (xx.x%)
Questionable or dubious definite	n (%)	xx (xx.x%)	xx (xx.x%)
Definite and tender	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Complications[2]*			
Total no-missing	n	xx	xx
None	n (%)	xx (xx.x%)	xx (xx.x%)
Erythema nodosum	n (%)	xx (xx.x%)	xx (xx.x%)
Pyoderma gangrenosum	n (%)	xx (xx.x%)	xx (xx.x%)
Other bowel-related fistula	n (%)	xx (xx.x%)	xx (xx.x%)
New fistula	n (%)	xx (xx.x%)	xx (xx.x%)
Arthritis or arthralgia	n (%)	xx (xx.x%)	xx (xx.x%)
Apthous ulcers	n (%)	xx (xx.x%)	xx (xx.x%)
Anal fissure, fistula or perirectal abscess	n (%)	xx (xx.x%)	xx (xx.x%)
Febrile (fever) episode over 100 degrees during past week	n (%)	xx (xx.x%)	xx (xx.x%)
Abscess	n (%)	xx (xx.x%)	xx (xx.x%)
Iritis or uveitis	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
HBI overall score[3]	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
SES-CD score	n	xx	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Patient status according to physician assessment			
Total no-missing	n	xx	xx
Remission	n (%)	xx (xx.x%)	xx (xx.x%)
Partial remission	n (%)	xx (xx.x%)	xx (xx.x%)
Not in remission	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

* More than an answer possible.

[1] Patients without HBI score registered in the medical chart.

[2] Patients with subscales of HBI registered in medical chart.

[3] Patients with HBI score registered or calculated.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 2.2.4 Disease Characteristics – UC patients

		VDZ (n=xx)	Other Biologic (n=xx)
Age at first ever UC diagnosis (years)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Location of UC at diagnosis*			
Total no-missing	n	xx	xx
Proctitis/proctosigmoiditis	n (%)	xx (xx.x%)	xx (xx.x%)
Left-sided (distal to splenic flexure)	n (%)	xx (xx.x%)	xx (xx.x%)
Extensive colitis (proximal to hepatic flexure)	n (%)	xx (xx.x%)	xx (xx.x%)
Unspecified	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

Table 2.2.5 Disease Activity – UC patients

		VDZ (n=xx)	Other Biologic (n=xx)
Time between index date and assessment (months)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Partial Mayo score registered in the medical chart?			

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Can any subscore of PMS be extracted from medical chart?[1]			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Stool frequency[2]			
Total no-missing	n	xx	xx
Unknown	n (%)	xx (xx.x%)	xx (xx.x%)
Normal number of stools for subject	n (%)	xx (xx.x%)	xx (xx.x%)
1-2 stools per day more than normal	n (%)	xx (xx.x%)	xx (xx.x%)
3-4 stools per day more than normal	n (%)	xx (xx.x%)	xx (xx.x%)
>=5 stools per day more than normal	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Rectal bleeding[2]			
Total no-missing	n	xx	xx
No blood seen	n (%)	xx (xx.x%)	xx (xx.x%)
Streaks of blood with stool less than half the time	n (%)	xx (xx.x%)	xx (xx.x%)
Obvious blood with stool most of the time	n (%)	xx (xx.x%)	xx (xx.x%)
Blood alone passes	n (%)	xx (xx.x%)	xx (xx.x%)

Property of Takeda: For Non Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
Missing	n	xx	xx
Physician global assessment[2]			
Total no-missing	n	xx	xx
Normal or remission	n (%)	xx (xx.x%)	xx (xx.x%)
Mild disease	n (%)	xx (xx.x%)	xx (xx.x%)
Moderate disease	n (%)	xx (xx.x%)	xx (xx.x%)
Severe disease	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Partial Mayo overall score[3]	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Patient status according to physician assessment			
Total no-missing	n	xx	xx
Remission	n (%)	xx (xx.x%)	xx (xx.x%)
Partial remission	n (%)	xx (xx.x%)	xx (xx.x%)
Not in remission	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

* More than an answer possible.

[1] Patients without partial Mayo score registered in the medical chart.

[2] Patients with subscores of PMS registered in medical chart.

[3] Patients with partial Mayo score registered or calculated.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 2.2.6 Diagnostic imaging

		VDZ (n=xx)	Other Biologic (n=xx)
Is there any endoscopy available?			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Indicate the situation[1]			
Total no-missing	n	xx	xx
Total remission	n (%)	xx (xx.x%)	xx (xx.x%)
Partial remission	n (%)	xx (xx.x%)	xx (xx.x%)
No remission	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

[1]Patients with endoscopy available.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 2.2.7 Laboratory determinations

	n	Mean (SD)	Median (Q1, Q3)	Min, Max	Missing
Time between assessment and index date (days)	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
PCR (mg/L)	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Fecal calprotectin (mg/Kg)	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Albumin (g/dL)	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
VSG (Mm/h)	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
AST (U/L)	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
ALT (U/L)	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Alcaline Phosphatase (U/L)	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Bilirubin (mg/dL)	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Creatinine (mg/dL)	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
BUN (mg/dL)	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Hemoglobin (g/dL)	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 2.2.8 Extra Intestinal Manifestations

		VDZ (n=xx)	Other Biologic (n=xx)
The patient has had extra intestinal manifestation within the 6 months prior the index date?			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Disease*[1]			
Total no-missing	n	xx	xx
Axial arthropathy	n (%)	xx (xx.x%)	xx (xx.x%)
Peripheral arthropathy	n (%)	xx (xx.x%)	xx (xx.x%)
Erythema nodosum	n (%)	xx (xx.x%)	xx (xx.x%)
Pyoderma gangrenosum	n (%)	xx (xx.x%)	xx (xx.x%)
Sweet's syndrome	n (%)	xx (xx.x%)	xx (xx.x%)
Oral alphthous ulcers	n (%)	xx (xx.x%)	xx (xx.x%)
Episcleritis	n (%)	xx (xx.x%)	xx (xx.x%)
Uveitis	n (%)	xx (xx.x%)	xx (xx.x%)
PSC	n (%)	xx (xx.x%)	xx (xx.x%)
Other	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Intensity*[2]			
Total no-missing	n	xx	xx
Mild	n (%)	xx (xx.x%)	xx (xx.x%)
Moderate	n (%)	xx (xx.x%)	xx (xx.x%)
Severe	n (%)	xx (xx.x%)	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
Missing	n	xx	xx
Ongoing at index date?[2]			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

[1]Patients with extra intestinal manifestation.

[2]Almost one extra intestinal manifestation.

* More than an answer possible.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 2.2.9 Comorbid medical conditions

		VDZ (n=xx)	Other Biologic (n=xx)
The patient has had comorbid medical condition within the 6 months prior the index date?			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Disease*[1]			
Total no-missing	n	xx	xx
Myocardial infection	n (%)	xx (xx.x%)	xx (xx.x%)
CHF	n (%)	xx (xx.x%)	xx (xx.x%)
Peripheral vascular disease	n (%)	xx (xx.x%)	xx (xx.x%)
CVA or TIA	n (%)	xx (xx.x%)	xx (xx.x%)
Dementia	n (%)	xx (xx.x%)	xx (xx.x%)
CPPD	n (%)	xx (xx.x%)	xx (xx.x%)
Connective tissue disease	n (%)	xx (xx.x%)	xx (xx.x%)
Peptic ulcer disease	n (%)	xx (xx.x%)	xx (xx.x%)
Liver disease	n (%)	xx (xx.x%)	xx (xx.x%)
Diabetes mellitus	n (%)	xx (xx.x%)	xx (xx.x%)
Hemiplegia	n (%)	xx (xx.x%)	xx (xx.x%)
Moderate to severe CKD	n (%)	xx (xx.x%)	xx (xx.x%)
Solid tumor	n (%)	xx (xx.x%)	xx (xx.x%)
Leukemia	n (%)	xx (xx.x%)	xx (xx.x%)
Lymphoma	n (%)	xx (xx.x%)	xx (xx.x%)
AIDS	n (%)	xx (xx.x%)	xx (xx.x%)
Other	n (%)	xx (xx.x%)	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
Missing	n	xx	xx
Intensity*[2]			
Total no-missing	n	xx	xx
Mild	n (%)	xx (xx.x%)	xx (xx.x%)
Moderate	n (%)	xx (xx.x%)	xx (xx.x%)
Severe	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Ongoing at index date?[2]			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

[1]Patients with comorbid medical condition.

[2]Almost one comorbid medical condition.

* More than an answer possible.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 2.2.10Biologic treatment pre index treatment

		VDZ (n=xx)	Other Biologic (n=xx)
Time between induction and index date (months)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Time between induction and maintenance (weeks)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Has there been intensification?			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
Increase the dose[1]	n (%)	xx (xx.x%)	xx (xx.x%)
Decrease the frequency[1]	n (%)	xx (xx.x%)	xx (xx.x%)
Both[1]	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Time between induction and intensification (months)[1]	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
	Missing	xx	xx
Time between induction and discontinuation (months)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Reason for discontinuation			
Total no-missing	n	xx	xx
Without primary response	n (%)	xx (xx.x%)	xx (xx.x%)
Lost of response	n (%)	xx (xx.x%)	xx (xx.x%)
Partial response	n (%)	xx (xx.x%)	xx (xx.x%)
Adverse event	n (%)	xx (xx.x%)	xx (xx.x%)
Remission	n (%)	xx (xx.x%)	xx (xx.x%)
Other	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

[1]Patients with intensification.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 2.2.11Non-biologic treatment

		VDZ (n=xx)	Other Biologic (n=xx)
Any non-biologic treatment administered within the 6 months prior the index date			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Type*[1]			
Total no-missing	n	xx	xx
Corticosteroids	n (%)	xx (xx.x%)	xx (xx.x%)
Immunomodulators	n (%)	xx (xx.x%)	xx (xx.x%)
Ant biotics	n (%)	xx (xx.x%)	xx (xx.x%)
5 – ASA	n (%)	xx (xx.x%)	xx (xx.x%)
Other	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Ongoing at index date?[1]			
Total no-missing	n	xx	xx
Yes[2]	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

[1]Patients with non-biologic treatment.

[2]Almost one non-biologic treatment.

* More than an answer possible.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 2.2.12End of study

		VDZ (n=xx)	Other Biologic (n=xx)
Has the patient finished the study prematurely			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Reason			
Total no-missing	n	xx	xx
Screening failure	n (%)	xx (xx.x%)	xx (xx.x%)
AE	n (%)	xx (xx.x%)	xx (xx.x%)
Patient decision	n (%)	xx (xx.x%)	xx (xx.x%)
Withdrawn consent	n (%)	xx (xx.x%)	xx (xx.x%)
Doctor's decision	n (%)	xx (xx.x%)	xx (xx.x%)
Other	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.2.3 By treatment (CD patients)

Table 2.3.1 Demographics (CD patients)

		VDZ (n=xx)	Other Biologic (n=xx)
Sex			
Total no-missing	n	xx	xx
Male	n (%)	xx (xx.x%)	xx (xx.x%)
Female	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
…			

…

9.2.4 By treatment line (CD-VDZ patients)

Table 2.4.1 Demographics (CD-VDZ patients)

		1st line (n=xx)	2nd line (n=xx)
Sex			
Total no-missing	n	xx	xx
Male	n (%)	xx (xx.x%)	xx (xx.x%)
Female	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
…			

…

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.2.5 By treatment line (CD-Other Biologic Patients)

Table 2.5.1 Demographics (CD-Other Biologic patients)

		1st line (n=xx)	2nd line (n=xx)
Sex			
Total no-missing	n	xx	xx
Male	n (%)	xx (xx.x%)	xx (xx.x%)
Female	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
…			

…

9.2.6 By treatment (UC patients)

Table 2.6.1 Demographics (UC patients)

		VDZ (n=xx)	Other Biologic (n=xx)
Sex			
Total no-missing	n	xx	xx
Male	n (%)	xx (xx.x%)	xx (xx.x%)
Female	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
…			

…

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.2.7 By treatment line (UC-VDZ patients)

Table 2.7.1 Demographics (UC-VDZ patients)

		1st line (n=xx)	2nd line (n=xx)
Sex			
Total no-missing	n	xx	xx
Male	n (%)	xx (xx.x%)	xx (xx.x%)
Female	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
…			

…

9.2.8 By treatment line (UC-Other Biologic Patients)

Table 2.8.1 Demographics (UC-Other Biologic patients)

		1st line (n=xx)	2nd line (n=xx)
Sex			
Total no-missing	n	xx	xx
Male	n (%)	xx (xx.x%)	xx (xx.x%)
Female	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
…			

…

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.3 Primary Objective (Descriptive analysis)

9.3.1 Descriptive by treatment

Table 3.1.1 Biologic index treatment I

		VDZ (n=xx)	Other Biologic (n=xx)
Steroid status at index date			
Total no-missing	n	xx	xx
Intolerant	n (%)	xx (xx.x%)	xx (xx.x%)
Dependent	n (%)	xx (xx.x%)	xx (xx.x%)
Refractory	n (%)	xx (xx.x%)	xx (xx.x%)
None of the above	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Main reason for starting biologic treatment at index date			
Total no-missing	n	xx	xx
Lack of/incomplete UC or CD response to prior non-biologic therapy	n (%)	xx (xx.x%)	xx (xx.x%)
Poor tolerability to prior non biologic therapy	n (%)	xx (xx.x%)	xx (xx.x%)
Lack of response to a prior Biologic	n (%)	xx (xx.x%)	xx (xx.x%)
Loss of response to a prior Biologic	n (%)	xx (xx.x%)	xx (xx.x%)
Partial response to a prior Biologic	n (%)	xx (xx.x%)	xx (xx.x%)
Poor tolerability to a prior Biologic	n (%)	xx (xx.x%)	xx (xx.x%)
Post-operative prophylaxis	n (%)	xx (xx.x%)	xx (xx.x%)
Subject choice	n (%)	xx (xx.x%)	xx (xx.x%)
Anticipated superior efficacy	n (%)	xx (xx.x%)	xx (xx.x%)
Anticipated superior safety	n (%)	xx (xx.x%)	xx (xx.x%)
Other Biologic contraindicated or not elig ble	n (%)	xx (xx.x%)	xx (xx.x%)
Route of administration	n (%)	xx (xx.x%)	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
Confidence in using biologic without concomitant immunomodulator	n (%)	xx (xx.x%)	xx (xx.x%)
Other	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Reason for starting biologic treatment at index date *			
Total no-missing	n	xx	xx
Lack of/incomplete UC or CD response to prior non-biologic therapy	n (%)	xx (xx.x%)	xx (xx.x%)
Poor tolerability to prior non biologic therapy	n (%)	xx (xx.x%)	xx (xx.x%)
Lack of response to a prior Biologic	n (%)	xx (xx.x%)	xx (xx.x%)
Loss of response to a prior Biologic	n (%)	xx (xx.x%)	xx (xx.x%)
Partial response to a prior Biologic	n (%)	xx (xx.x%)	xx (xx.x%)
Poor tolerability to a prior Biologic	n (%)	xx (xx.x%)	xx (xx.x%)
Post-operative prophylaxis	n (%)	xx (xx.x%)	xx (xx.x%)
Subject choice	n (%)	xx (xx.x%)	xx (xx.x%)
Anticipated superior efficacy	n (%)	xx (xx.x%)	xx (xx.x%)
Anticipated superior safety	n (%)	xx (xx.x%)	xx (xx.x%)
Other Biologic contraindicated or not elig ble	n (%)	xx (xx.x%)	xx (xx.x%)
Route of administration	n (%)	xx (xx.x%)	xx (xx.x%)
Confidence in using biologic without concomitant immunomodulator	n (%)	xx (xx.x%)	xx (xx.x%)
Other	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

* More than an answer possible.

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 3.1.2 Biologic index treatment II

		VDZ (n=xx)	Other Biologic (n=xx)
Type of biologic			
Total no-missing	n		xx
Original	n (%)		xx (xx.x%)
Infliximab	n (%)		xx (xx.x%)
Biosimilar	n (%)		xx (xx.x%)
Adalimumab	n (%)		xx (xx.x%)
Golimumab	n (%)		xx (xx.x%)
Missing	n		xx
Posology (mg) (Induction)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Posology (mg) (Maintenance)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Time between induction and maintenance (weeks)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
	Missing	xx	xx
Is the treatment ongoing?			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Reason for discontinuation[2]			
Total no-missing	n	xx	xx
Without primary response	n (%)	xx (xx.x%)	xx (xx.x%)
Loss of response	n (%)	xx (xx.x%)	xx (xx.x%)
Partial response	n (%)	xx (xx.x%)	xx (xx.x%)
Adverse event	n (%)	xx (xx.x%)	xx (xx.x%)
Remission	n (%)	xx (xx.x%)	xx (xx.x%)
Other	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Has the patient take a new biologic treatment?[2]			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Time between index treatment and new treatment (months)[3]	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		VDZ (n=xx)	Other Biologic (n=xx)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Posology (mg) (New treatment induction)[3]	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Type of biologic[3]			
Total no-missing	n	xx	xx
VDZ	n (%)		xx (xx.x%)
Infliximab	n (%)	xx (xx.x%)	xx (xx.x%)
Adalimumab	n (%)	xx (xx.x%)	xx (xx.x%)
Golimumab	n (%)	xx (xx.x%)	xx (xx.x%)
Ustekinumab	n (%)	xx (xx.x%)	xx (xx.x%)
Certolizumab	n (%)	xx (xx.x%)	xx (xx.x%)
Tofacitinib	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

[1]Patients with intensification.

[2]Patients with treatment discontinuation.

[3]Patients with new biologic treatment.

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 3.1.3 Follow-up

		VDZ (n=xx)	Other Biologic (n=xx)
Time of follow-up (months)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 3.1.4 Concomitant treatment

		VDZ (n=xx)	Other Biologic (n=xx)
Any concomitant medication during induction			
Total no-missing	n	xx	xx
No	n (%)	xx (xx.x%)	xx (xx.x%)
Yes*	n (%)	xx (xx.x%)	xx (xx.x%)
Corticosteroids	n (%)	xx (xx.x%)	xx (xx.x%)
Immunomodulators	n (%)	xx (xx.x%)	xx (xx.x%)
Antibiotics	n (%)	xx (xx.x%)	xx (xx.x%)
5 – ASA	n (%)	xx (xx.x%)	xx (xx.x%)
Others	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Any concomitant medication during maintenance			
Total no-missing	n	xx	xx
No	n (%)	xx (xx.x%)	xx (xx.x%)
Yes*	n (%)	xx (xx.x%)	xx (xx.x%)
Corticosteroids	n (%)	xx (xx.x%)	xx (xx.x%)
Immunomodualtors	n (%)	xx (xx.x%)	xx (xx.x%)
Antibiotics	n (%)	xx (xx.x%)	xx (xx.x%)
5 – ASA	n (%)	xx (xx.x%)	xx (xx.x%)
Others	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

* More than an answer possible.

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.3.2 By treatment (CD patients)

Table 3.2.1 Biologic index treatment I (CD patients)

		VDZ (n=xx)	Other Biologic (n=xx)
Steroid status at index date			
Total no-missing	n	xx	xx
Intolerant	n (%)	xx (xx.x%)	xx (xx.x%)
Dependent	n (%)	xx (xx.x%)	xx (xx.x%)
Refractory	n (%)	xx (xx.x%)	xx (xx.x%)
None of the above	n (%)	xx (xx.x%)	xx (xx.x%)
…			

…

9.3.3 By treatment line (CD-VDZ patients)

Table 3.3.1 Biologic index treatment I (CD-VDZ patients)

		1st line (n=xx)	2nd line (n=xx)
Steroid status at index date			
Total no-missing	n	xx	xx
Intolerant	n (%)	xx (xx.x%)	xx (xx.x%)
Dependent	n (%)	xx (xx.x%)	xx (xx.x%)
Refractory	n (%)	xx (xx.x%)	xx (xx.x%)
None of the above	n (%)	xx (xx.x%)	xx (xx.x%)
…			

…

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.3.4 By treatment line (CD-Other Biologic Patients)

Table 3.4.1 Biologic index treatment I (CD-Other Biologic patients)

		1st line (n=xx)	2nd line (n=xx)
Steroid status at index date			
Total no-missing	n	xx	xx
Intolerant	n (%)	xx (xx.x%)	xx (xx.x%)
Dependent	n (%)	xx (xx.x%)	xx (xx.x%)
Refractory	n (%)	xx (xx.x%)	xx (xx.x%)
None of the above	n (%)	xx (xx.x%)	xx (xx.x%)
…			

…

9.3.5 By treatment (UC patients)

Table 3.5.1 Biologic index treatment I (UC patients)

		VDZ (n=xx)	Other Biologic (n=xx)
Steroid status at index date			
Total no-missing	n	xx	xx
Intolerant	n (%)	xx (xx.x%)	xx (xx.x%)
Dependent	n (%)	xx (xx.x%)	xx (xx.x%)
Refractory	n (%)	xx (xx.x%)	xx (xx.x%)
None of the above	n (%)	xx (xx.x%)	xx (xx.x%)
…			

…

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.3.6 By treatment line (UC-VDZ patients)

Table 3.6.1 Biologic index treatment I (UC-VDZ patients)

		1st line (n=xx)	2nd line (n=xx)
Steroid status at index date			
Total no-missing	n	xx	xx
Intolerant	n (%)	xx (xx.x%)	xx (xx.x%)
Dependent	n (%)	xx (xx.x%)	xx (xx.x%)
Refractory	n (%)	xx (xx.x%)	xx (xx.x%)
None of the above	n (%)	xx (xx.x%)	xx (xx.x%)
…			

…

9.3.7 By treatment line (UC-Other Biologic Patients)

Table 3.7.1 Biologic index treatment I (UC-Other Biologic patients)

		1st line (n=xx)	2nd line (n=xx)
Steroid status at index date			
Total no-missing	n	xx	xx
Intolerant	n (%)	xx (xx.x%)	xx (xx.x%)
Dependent	n (%)	xx (xx.x%)	xx (xx.x%)
Refractory	n (%)	xx (xx.x%)	xx (xx.x%)
None of the above	n (%)	xx (xx.x%)	xx (xx.x%)
…			

…

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.4 Primary objective (Endpoint analysis)

9.4.1 PS-IPTW

Table 4.1.1 Descriptive analysis pre and post PS-IPTW (CD patients)

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Age at index date (years)		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Sex	Male	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Female	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Time between first ever CD diagnosis and index date (years)		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Smoking status at index treatment initiation	Never smoked	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Former smoker	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Current smoker	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
HBI overall score		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Perianal disease at diagnosis	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Previous abdominal surgeries	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Previous perianal surgeries	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Location of intestinal involvement at diagnosis	Ileal	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Colonic/Ileocolonic	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Type of disease behaviour at diagnosis	Inflammatory	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Stricturing/Penetrating	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Treatment line	First biologic (bionaive)	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Second biologic	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Any Corticosteroids treatment administered within the 6 months prior the index date	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Any Immunomodulators treatment administered within the 6 months prior the index date	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
PCR (mg/L)[LOG]		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Fecal calprotectin (mg/Kg)[LOG]		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
The patient has had extra intestinal manifestation within the 6 months prior the index date?	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Figure 4.1.1 Density Plot – pre PS-IPTW (CD)

Figure 4.1.2 Density Plot – Post-IPTW (CD)

Figure 4.1.3 Love Plot (CD)

Figure 4.1.4 Box Plots (CD)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.1.2 Descriptive analysis pre and post PS-IPTW (UC patients)

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Age at index date (years)		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Sex	Male	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Female	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Time between first ever UC diagnosis and index date (years)		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Smoking status at index treatment initiation	Never smoked	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Former smoker	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Current smoker	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Partial Mayo score		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Previous abdominal surgeries	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Location of intestinal involvement at diagnosis	Proctitis/proctosigmoiditis / Left-sided	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Extensive colitis	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Treatment line	First biologic (bionaive)	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Second biologic	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Any Corticosteroids treatment administered within the 6 months prior the index date	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Any Immunomodulators treatment administered within the 6 months prior the index date	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
PCR (mg/L)[LOG]		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Fecal calprotectin (mg/Kg)[LOG]		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
The patient has had extra intestinal manifestation within the 6 months prior the index date?	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Figure 4.1.5 Density Plot – pre PS-IPTW (UC)

Figure 4.1.6 Density Plot – Post-IPTW (UC)

Figure 4.1.7 Love Plot (UC)

Figure 4.1.8 Box Plots (UC)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.1.3 Descriptive analysis pre and post PS-IPTW (CD patients – First line)

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Age at index date (years)		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Sex	Male	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Female	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Time between first ever CD diagnosis and index date (years)		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Smoking status at index treatment initiation	Never smoked	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Former smoker	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Current smoker	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
HBI overall score		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Perianal disease at diagnosis	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Previous abdominal surgeries	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Previous perianal surgeries	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Location of intestinal involvement at diagnosis	Ileal	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Colonic/Ileocolonic	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Type of disease behaviour at diagnosis	Inflammatory	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Stricturing/Penetrating	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Any Corticosteroids treatment administered within the 6 months prior the index date	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Any Immunomodulators treatment administered within the 6 months prior the index date	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
PCR (mg/L)[LOG]		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Fecal calprotectin (mg/Kg)[LOG]		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
The patient has had extra intestinal manifestation within the 6 months prior the index date?	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Figure 4.1.9 Density Plot – pre PS-IPTW (CD – First line)

Figure 4.1.10 Density Plot – Post-IPTW (CD – First line)

Figure 4.1.11 Love Plot (CD – First line)

Figure 4.1.12 Box Plots (CD – First line)

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.1.4 Descriptive analysis pre and post PS-IPTW (UC patients – First line)

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Age at index date (years)		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Sex	Male	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Female	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Time between first ever UC diagnosis and index date (years)		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Smoking status at index treatment initiation	Never smoked	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Former smoker	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Current smoker	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Partial Mayo score		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Previous abdominal surgeries	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Location of intestinal involvement at diagnosis	Proctitis/proctosigmoiditis / Left-sided	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Extensive colitis	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Any Corticosteroids treatment administered within the 6 months prior the index date	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Any Immunomodulators treatment administered within the 6 months prior the index date	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
PCR (mg/L)[LOG]		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Fecal calprotectin (mg/Kg)[LOG]		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
The patient has had extra intestinal manifestation within the 6 months prior the index date?	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Figure 4.1.13 Density Plot – pre PS-IPTW (UC – First line)

Figure 4.1.14 Density Plot – Post-IPTW (UC – First line)

Figure 4.1.15 Love Plot (UC – First line)

Figure 4.1.16 Box Plots (UC – First line)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.1.5 Descriptive analysis pre and post PS-IPTW (CD patients – Second line)

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Age at index date (years)		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Sex	Male	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Female	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Time between first ever CD diagnosis and index date (years)		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Smoking status at index treatment initiation	Never smoked	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Former smoker	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Current smoker	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
HBI overall score		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Perianal disease at diagnosis	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Previous abdominal surgeries	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Previous perianal surgeries	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Location of intestinal involvement at diagnosis	Ileal	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Colonic/Ileocolonic	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Type of disease behaviour at diagnosis	Inflammatory	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Stricturing/Penetrating	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Any Corticosteroids treatment administered within the 6 months prior the index date	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Any Immunomodulators treatment administered within the 6 months prior the index date	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
PCR (mg/L)[LOG]		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Fecal calprotectin (mg/Kg)[LOG]		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
The patient has had extra intestinal manifestation within the 6 months prior the index date?	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Reason for discontinuation (First line)	Primary failure	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
	Secondary failure	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Safety	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Other	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Figure 4.1.17 Density Plot – pre PS-IPTW (CD – Second line)

Figure 4.1.18 Density Plot – Post-IPTW (CD – Second line)

Figure 4.1.19 Love Plot (CD – Second line)

Figure 4.1.20 Box Plots (CD – Second line)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.1.6 Descriptive analysis pre and post PS-IPTW (UC patients – Second line)

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Age at index date (years)		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Sex	Male	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Female	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Time between first ever UC diagnosis and index date (years)		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Smoking status at index treatment initiation	Never smoked	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Former smoker	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Current smoker	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Partial Mayo score		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Previous abdominal surgeries	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Location of intestinal involvement at diagnosis	Proctitis/proctosigmoiditis / Left-sided	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Extensive colitis	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

			Pre PS-IPTW		Post PS-IPTW	
			VDZ (n=xx)	Other Biologic (n=xx)	VDZ (n=xx)	Other Biologic (n=xx)
Any Corticosteroids treatment administered within the 6 months prior the index date	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Any Immunomodulators treatment administered within the 6 months prior the index date	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
PCR (mg/L)[LOG]		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Fecal calprotectin (mg/Kg)[LOG]		Mean (SE)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
The patient has had extra intestinal manifestation within the 6 months prior the index date?	Yes	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	No	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
Reason for discontinuation (First line)	Primary failure	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Secondary failure	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Safety	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)
	Other	n (%)	xx.x (xx.x)	xx.xx (xx.x)	xx.x (xx.x)	xx.xx (xx.x)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Figure 4.1.21 Density Plot – pre PS-IPTW (UC – Second line)

Figure 4.1.22 Density Plot – Post-IPTW (UC – Second line)

Figure 4.1.23 Love Plot (UC – Second line)

Figure 4.1.24 Box Plots (UC – Second line)

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

9.4.2 Discontinuation

Table 4.2.1 Discontinuation

	1st group		2nd group			
	Total no-missing	Patients with discontinuation	Total no-missing	Patients with discontinuation		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
CD						
VDZ – 1st line Vs. VDZ – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal Vs. VDZ – Colonic/Ileocolonic[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 1st line Vs. VDZ – Colonic/Ileocolonic – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 2nd line Vs. VDZ – Colonic/Ileocolonic – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – Intensification Vs. VDZ – Colonic/Ileocolonic – Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – No Intensification Vs. VDZ – Colonic/Ileocolonic – No Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with discontinuation	Total no-missing	Patients with discontinuation		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory Vs. VDZ – Stricturing/Penetrating[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 1st line Vs. VDZ – Stricturing/Penetrating – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 2nd line Vs. VDZ – Stricturing/Penetrating – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 1st line Vs. O.B. – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal Vs. O.B. – Colonic/Ileocolonic[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – 1st line Vs. O.B. – Colonic/Ileocolonic – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – 2nd line Vs. O.B. – Colonic/Ileocolonic – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – Intensification Vs. O.B. – Colonic/Ileocolonic – Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – No Intensification Vs. O.B. – Colonic/Ileocolonic – No Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with discontinuation	Total no-missing	Patients with discontinuation		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory Vs. O.B. – Stricturing/Penetrating[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Vs. O.B.[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. O.B. 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. O.B. 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic Vs. O.B. – Colonic/Ileocolonic[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic – 1st line Vs. O.B. – Colonic/Ileocolonic 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic – 2nd line Vs. O.B. – Colonic/Ileocolonic 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with discontinuation	Total no-missing	Patients with discontinuation		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
VDZ – Ileal Vs. O.B. – Ileal[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 1st line Vs. O.B. – Ileal – 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 2nd line Vs. O.B. – Ileal – 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory Vs. O.B. – Inflamatory[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with discontinuation	Total no-missing	Patients with discontinuation		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
VDZ – Inflamatory – 1st line Vs. O.B. – Inflamatory – 1st line [3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 2nd line Vs. O.B. – Inflamatory – 2nd line [4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating Vs. O.B. – Stricturing/Penetrating [2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line [3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line [4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
UC						
VDZ – 1st line Vs. VDZ – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis Vs. VDZ – Proctitis/Left colitis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 1st line Vs. VDZ – Proctitis/Left colitis – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 2nd line Vs. VDZ – Proctitis/Left colitis – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – Intensification Vs. VDZ – Proctitis/Left colitis – Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with discontinuation	Total no-missing	Patients with discontinuation		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
VDZ – Extensive colitis – No Intensification Vs. VDZ – Proctitis/Left colitis – No Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 1st line Vs. O.B. – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis Vs. O.B. – Proctitis/Left colitis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – 1st line Vs. O.B. – Proctitis/Left colitis – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – 2nd line Vs. O.B. – Proctitis/Left colitis – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – Intensification Vs. O.B. – Proctitis/Left colitis – Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with discontinuation	Total no-missing	Patients with discontinuation		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
O.B. – Extensive colitis – No Intensification Vs. O.B. – Proctitis/Left colitis – No Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Vs. O.B.[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. O.B. 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. O.B. 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis Vs. O.B. – Proctitis/Left colitis[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis – 1st line Vs. O.B. – Proctitis/Left colitis 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis – 2nd line Vs. O.B. – Proctitis/Left colitis 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with discontinuation	Total no-missing	Patients with discontinuation		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
VDZ – Extensive colitis Vs. O.B. – Extensive colitis[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 1st line Vs. O.B. – Extensive colitis – 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 2nd line Vs. O.B. – Extensive colitis – 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

*Estimated with a logistic regression.

[1]Data without PS-IPTW.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

[2]Data with PS-IPTW (CD).

[3]Data with PS-IPTW (CD-1st line).

[4]Data with PS-IPTW (CD-2nd line).

[5]Data with PS-IPTW (UC).

[6]Data with PS-IPTW (UC-1st line).

[7]Data with PS-IPTW (UC-2nd line).

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.2.2 CD patients with VDZ – Discontinuation Logistic regression model (p-values)

	n	Missing	p-value
Model	xx	xx	
Line treatment			x.xxxx
Type of diagnosis			x.xxxx
Disease duration			x.xxxx
Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment and Type of diagnosis			x.xxxx
Interaction Line treatment and Disease duration			x.xxxx
Interaction Line treatment and Type of disease behaviour at diagnosis			x.xxxx
Interaction Type of diagnosis and Disease duration			x.xxxx
Interaction Type of diagnosis and Type of disease behaviour at diagnosis			x.xxxx
Interaction Disease duration and Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment, Type of diagnosis and Disease duration			x.xxxx
Interaction Line treatment, Type of diagnosis and Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment, Disease duration and Type of disease behaviour at diagnosis			x.xxxx
Interaction Type of diagnosis, Disease duration and Type of disease behaviour at diagnosis			x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	n	Missing	p-value
Interaction Line treatment, Type of diagnosis, Disease duration and Type of disease behaviour at diagnosis			x.xxxx

Table 4.2.3 CD patients with VDZ – Discontinuation Logistic regression model (estimated OR)

		OR (CI 95%)
Line Treatment	2nd line Vs. 1st line	xx.x (xx.x, xx.x)
Type of diagnosis	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
Line Treatment	2 years or more Vs. less than 2 years	xx.x (xx.x, xx.x)
Type of disease behaviour at diagnosis	Inflammatory Vs. Stricturing / Penetrating	xx.x (xx.x, xx.x)
Interaction Line treatment and Type of diagnosis		
2nd line	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
1st line	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
…		

Note: Only significant variables and/or interactions (Table 4.1.3) will be included in this table.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Table 4.2.4 UC patients with VDZ – Discontinuation Logistic regression model (p-values)

	n	Missing	p-value
Model	xx	xx	
Line treatment			x.xxxx
Type of diagnosis			x.xxxx
Disease duration			x.xxxx
Interaction Line treatment and Type of diagnosis			x.xxxx
Interaction Line treatment and Disease duration			x.xxxx
Interaction Type of diagnosis and Disease duration			x.xxxx
Interaction Line treatment, Type of diagnosis and Disease duration			x.xxxx

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.2.5 UC patients with VDZ – Discontinuation Logistic regression model (estimated OR)

		OR (CI 95%)
Line Treatment	2nd line Vs. 1st line	xx.x (xx.x, xx.x)
Type of diagnosis	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
Line Treatment	2 years or more Vs. less than 2 years	xx.x (xx.x, xx.x)
Interaction Line treatment and Type of diagnosis		
2nd line	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
1st line	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
…		

Note: Only significant variables and/or interactions (Table 4.1.3) will be included in this table.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.2.6 CD patients with Other Biologic – Discontinuation Logistic regression model (p-values)

	n	Missing	p-value
Model	xx	xx	
Line treatment			x.xxxx
Type of diagnosis			x.xxxx
Disease duration			x.xxxx
Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment and Type of diagnosis			x.xxxx
Interaction Line treatment and Disease duration			x.xxxx
Interaction Line treatment and Type of disease behaviour at diagnosis			x.xxxx
Interaction Type of diagnosis and Disease duration			x.xxxx
Interaction Type of diagnosis and Type of disease behaviour at diagnosis			x.xxxx
Interaction Disease duration and Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment, Type of diagnosis and Disease duration			x.xxxx
Interaction Line treatment, Type of diagnosis and Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment, Disease duration and Type of disease behaviour at diagnosis			x.xxxx
Interaction Type of diagnosis, Disease duration and Type of disease behaviour at diagnosis			x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	n	Missing	p-value
Interaction Line treatment, Type of diagnosis, Disease duration and Type of disease behaviour at diagnosis			x.xxxx

Table 4.2.7 CD patients with Other Biologic – Discontinuation Logistic regression model (estimated OR)

		OR (CI 95%)
Line Treatment	2nd line Vs. 1st line	xx.x (xx.x, xx.x)
Type of diagnosis	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
Line Treatment	2 years or more Vs. less than 2 years	xx.x (xx.x, xx.x)
Type of disease behaviour at diagnosis	Inflammatory Vs. Stricturing / Penetrating	xx.x (xx.x, xx.x)
Interaction Line treatment and Type of diagnosis		
2nd line	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
1st line	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
…		

Note: Only significant variables and/or interactions (Table 4.1.3) will be included in this table.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Table 4.2.8 UC patients with Other Biologic – Discontinuation Logistic regression model (p-values)

	n	Missing	p-value
Model	xx	xx	
Line treatment			x.xxxx
Type of diagnosis			x.xxxx
Disease duration			x.xxxx
Interaction Line treatment and Type of diagnosis			x.xxxx
Interaction Line treatment and Disease duration			x.xxxx
Interaction Type of diagnosis and Disease duration			x.xxxx
Interaction Line treatment, Type of diagnosis and Disease duration			x.xxxx

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.2.9 UC patients with Other Biologic – Discontinuation Logistic regression model (estimated OR)

		OR (CI 95%)
Line Treatment	2nd line Vs. 1st line	xx.x (xx.x, xx.x)
Type of diagnosis	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
Line Treatment	2 years or more Vs. less than 2 years	xx.x (xx.x, xx.x)
Interaction Line treatment and Type of diagnosis		
2nd line	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
1st line	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
…		

Note: Only significant variables and/or interactions (Table 4.1.3) will be included in this table.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.4.3 Time to treatment discontinuation

Table 4.3.1 Time to treatment discontinuation (Months)

	1st group		2nd group		
	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	p-value***
CD					
VDZ – 1st line Vs. VDZ – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal Vs. VDZ – Colonic/Ileocolonic[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 1st line Vs. VDZ – Colonic/Ileocolonic – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 2nd line Vs. VDZ – Colonic/Ileocolonic – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – Intensification Vs. VDZ – Colonic/Ileocolonic – Intesification[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – No Intensification Vs. VDZ – Colonic/Ileocolonic – No Intesification[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory Vs. VDZ – Stricturing/Penetrating[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	p-value***
VDZ – Inflamatory – 1st line Vs. VDZ – Stricturing/Penetrating – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 2nd line Vs. VDZ – Stricturing/Penetrating – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 1st line Vs. O.B. – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal Vs. O.B. – Colonic/Ileocolonic[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – 1st line Vs. O.B. – Colonic/Ileocolonic – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – 2nd line Vs. O.B. – Colonic/Ileocolonic – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – Intensification Vs. O.B. – Colonic/Ileocolonic – Intesification[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – No Intensification Vs. O.B. – Colonic/Ileocolonic – No Intesification[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory Vs. O.B. – Stricturing/Penetrating[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	p-value***
O.B. – Inflamatory – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Vs. O.B.[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. O.B. 1st line[3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. O.B. 2nd line[4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic Vs. O.B. – Colonic/Ileocolonic[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic – 1st line Vs. O.B. – Colonic/Ileocolonic 1st line[3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic – 2nd line Vs. O.B. – Colonic/Ileocolonic 2nd line[4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal Vs. O.B. – Ileal[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 1st line Vs. O.B. – Ileal – 1st line[3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 2nd line Vs. O.B. – Ileal – 2nd line[4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	p-value***
VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory Vs. O.B. – Inflamatory[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 1st line Vs. O.B. – Inflamatory – 1st line[3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 2nd line Vs. O.B. – Inflamatory – 2nd line[4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating Vs. O.B. – Stricturing/Penetrating[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line[3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line[4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
UC					
VDZ – 1st line Vs. VDZ – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis Vs. VDZ – Proctitis/Left colitis[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 1st line Vs. VDZ – Proctitis/Left colitis – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	p-value***
VDZ – Extensive colitis – 2nd line Vs. VDZ – Proctitis/Left colitis – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – Intensification Vs. VDZ – Proctitis/Left colitis – Intesification[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – No Intensification Vs. VDZ – Proctitis/Left colitis – No Intesification[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 1st line Vs. O.B. – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis Vs. O.B. – Proctitis/Left colitis[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – 1st line Vs. O.B. – Proctitis/Left colitis – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – 2nd line Vs. O.B. – Proctitis/Left colitis – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – Intensification Vs. O.B. – Proctitis/Left colitis – Intesification[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	p-value***
O.B. – Extensive colitis – No Intensification Vs. O.B. – Proctitis/Left colitis – No Intesification[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Vs. O.B.[5]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. O.B. 1st line[6]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. O.B. 2nd line[7]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis Vs. O.B. – Proctitis/Left colitis[5]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis – 1st line Vs. O.B. – Proctitis/Left colitis 1st line[6]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis – 2nd line Vs. O.B. – Proctitis/Left colitis 2nd line[7]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis Vs. O.B. – Extensive colitis[5]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 1st line Vs. O.B. – Extensive colitis – 1st line[6]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 2nd line Vs. O.B. – Extensive colitis – 2nd line[7]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	Total no-missing* n	Time to treatment discontinuation** Median(Q1,Q3)	p-value***
VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[5]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[6]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[7]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[5]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[6]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[7]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

* Patients with correct data to calculate “time to treatment discontinuation”.

** Estimated with Kaplan-Meier method.

*** Estimated with LogRank test.

[1]Data without PS-IPTW.

[2]Data with PS-IPTW (CD).

[3]Data with PS-IPTW (CD-1st line).

[4]Data with PS-IPTW (CD-2nd line).

[5]Data with PS-IPTW (UC).

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

[6]Data with PS-IPTW (UC-1st line).

[7]Data with PS-IPTW (UC-2nd line).

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

9.4.4 Duration of treatment

Table 4.4.1 Duration of treatment (Months)

	1st group		2nd group		
	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	p-value***
CD					
VDZ – 1st line Vs. VDZ – 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal Vs. VDZ – Colonic/Ileocolonic[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 1st line Vs. VDZ – Colonic/Ileocolonic – 1st line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 2nd line Vs. VDZ – Colonic/Ileocolonic – 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – Intensification Vs. VDZ – Colonic/Ileocolonic – Intesification[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – No Intensification Vs. VDZ – Colonic/Ileocolonic – No Intesification[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory Vs. VDZ – Stricturing/Penetrating[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	p-value***
VDZ – Inflamatory – 1st line Vs. VDZ – Stricturing/Penetrating – 1st line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 2nd line Vs. VDZ – Stricturing/Penetrating – 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 1st line Vs. O.B. – 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal Vs. O.B. – Colonic/Ileocolonic[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – 1st line Vs. O.B. – Colonic/Ileocolonic – 1st line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – 2nd line Vs. O.B. – Colonic/Ileocolonic – 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – Intensification Vs. O.B. – Colonic/Ileocolonic – Intesification[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – No Intensification Vs. O.B. – Colonic/Ileocolonic – No Intesification[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory Vs. O.B. – Stricturing/Penetrating[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	p-value***
O.B. – Inflamatory – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Vs. O.B.[2]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. O.B. 1st line[3]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. O.B. 2nd line[4]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic Vs. O.B. – Colonic/Ileocolonic[2]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic – 1st line Vs. O.B. – Colonic/Ileocolonic 1st line[3]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic – 2nd line Vs. O.B. – Colonic/Ileocolonic 2nd line[4]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal Vs. O.B. – Ileal[2]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 1st line Vs. O.B. – Ileal – 1st line[3]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 2nd line Vs. O.B. – Ileal – 2nd line[4]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[2]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[3]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[4]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[2]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	p-value***
VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[3]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[4]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory Vs. O.B. – Inflamatory[2]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 1st line Vs. O.B. – Inflamatory – 1st line[3]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 2nd line Vs. O.B. – Inflamatory – 2nd line[4]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating Vs. O.B. – Stricturing/Penetrating[2]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line[3]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line[4]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
UC					
VDZ – 1st line Vs. VDZ – 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis Vs. VDZ – Proctitis/Left colitis[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 1st line Vs. VDZ – Proctitis/Left colitis – 1st line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	p-value***
VDZ – Extensive colitis – 2nd line Vs. VDZ – Proctitis/Left colitis – 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – Intensification Vs. VDZ – Proctitis/Left colitis – Intesification[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – No Intensification Vs. VDZ – Proctitis/Left colitis – No Intesification[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 1st line Vs. O.B. – 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis Vs. O.B. – Proctitis/Left colitis[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – 1st line Vs. O.B. – Proctitis/Left colitis – 1st line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – 2nd line Vs. O.B. – Proctitis/Left colitis – 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – Intensification Vs. O.B. – Proctitis/Left colitis – Intesification[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	p-value***
O.B. – Extensive colitis – No Intensification Vs. O.B. – Proctitis/Left colitis – No Intesification[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Vs. O.B.[5]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. O.B. 1st line[6]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. O.B. 2nd line[7]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis Vs. O.B. – Proctitis/Left colitis[5]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis – 1st line Vs. O.B. – Proctitis/Left colitis 1st line[6]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis – 2nd line Vs. O.B. – Proctitis/Left colitis 2nd line[7]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis Vs. O.B. – Extensive colitis[5]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 1st line Vs. O.B. – Extensive colitis – 1st line[6]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 2nd line Vs. O.B. – Extensive colitis – 2nd line[7]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	Total no-missing* n (n_1 - n_2)	Duration of treatment** Median(Q1,Q3)	p-value***
VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[5]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[6]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[7]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[5]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[6]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[7]	xx (xx – xx)	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

*Patients with correct data to calculate "duration of treatment". n_1: Patients treatment discontinued. n_2: Patients treatment continue.

**Estimated with Kaplan-Meier method.

***LogRank test test.

[1]Data without PS-IPTW.

[2]Data with PS-IPTW (CD).

[3]Data with PS-IPTW (CD-1st line).

[4]Data with PS-IPTW (CD-2nd line).

[5]Data with PS-IPTW (UC).

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

[6]Data with PS-IPTW (UC-1st line).

[7]Data with PS-IPTW (UC-2nd line).

Figure 4.4.1 Duration of treatment (months)

For each comparison a figure with Kaplan-Meier's curves will presented.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

9.4.5 Intensification

Table 4.5.1 Patients with one intensification or more (%)

	1st group		2nd group			
	Total no-missing n	Patients with one intensification or more n(%)	Total no-missing n	Patients with one intensification or more n(%)	OR (IC95%)*	p-value*
CD						
VDZ – 1st line Vs. VDZ – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal Vs. VDZ – Colonic/Ileocolonic[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 1st line Vs. VDZ – Colonic/Ileocolonic – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 2nd line Vs. VDZ – Colonic/Ileocolonic – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – Intensification Vs. VDZ – Colonic/Ileocolonic – Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – No Intensification Vs. VDZ – Colonic/Ileocolonic – No Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing n	Patients with one intensification or more n(%)	Total no-missing n	Patients with one intensification or more n(%)	OR (IC95%)*	p-value*
VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory Vs. VDZ – Stricturing/Penetrating[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 1st line Vs. VDZ – Stricturing/Penetrating – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 2nd line Vs. VDZ – Stricturing/Penetrating – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 1st line Vs. O.B. – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal Vs. O.B. – Colonic/Ileocolonic[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – 1st line Vs. O.B. – Colonic/Ileocolonic – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – 2nd line Vs. O.B. – Colonic/Ileocolonic – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – Intensification Vs. O.B. – Colonic/Ileocolonic – Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – No Intensification Vs. O.B. – Colonic/Ileocolonic – No Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing n	Patients with one intensification or more n(%)	Total no-missing n	Patients with one intensification or more n(%)	OR (IC95%)*	p-value*
O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory Vs. O.B. – Stricturing/Penetrating[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Vs. O.B.[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. O.B. 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. O.B. 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic Vs. O.B. – Colonic/Ileocolonic[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing n	Patients with one intensification or more n(%)	Total no-missing n	Patients with one intensification or more n(%)	OR (IC95%)*	p-value*
VDZ – Colonic/Ileocolonic – 1st line Vs. O.B. – Colonic/Ileocolonic 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic – 2nd line Vs. O.B. – Colonic/Ileocolonic 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal Vs. O.B. – Ileal[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 1st line Vs. O.B. – Ileal – 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 2nd line Vs. O.B. – Ileal – 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing n	Patients with one intensification or more n(%)	Total no-missing n	Patients with one intensification or more n(%)	OR (IC95%)*	p-value*
VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory Vs. O.B. – Inflamatory[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 1st line Vs. O.B. – Inflamatory – 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 2nd line Vs. O.B. – Inflamatory – 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating Vs. O.B. – Stricturing/Penetrating[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
UC						
VDZ – 1st line Vs. VDZ – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis Vs. VDZ – Proctitis/Left colitis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing n	Patients with one intensification or more n(%)	Total no-missing n	Patients with one intensification or more n(%)	OR (IC95%)*	p-value*
VDZ – Extensive colitis – 1st line Vs. VDZ – Proctitis/Left colitis – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 2nd line Vs. VDZ – Proctitis/Left colitis – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – Intensification Vs. VDZ – Proctitis/Left colitis – Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – No Intensification Vs. VDZ – Proctitis/Left colitis – No Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 1st line Vs. O.B. – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis Vs. O.B. – Proctitis/Left colitis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing n	Patients with one intensification or more n(%)	Total no-missing n	Patients with one intensification or more n(%)	OR (IC95%)*	p-value*
O.B. – Extensive colitis – 1st line Vs. O.B. – Proctitis/Left colitis – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – 2nd line Vs. O.B. – Proctitis/Left colitis – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – Intensification Vs. O.B. – Proctitis/Left colitis – Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – No Intensification Vs. O.B. – Proctitis/Left colitis – No Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Vs. O.B.[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. O.B. 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing n	Patients with one intensification or more n(%)	Total no-missing n	Patients with one intensification or more n(%)	OR (IC95%)*	p-value*
VDZ – 2nd line Vs. O.B. 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis Vs. O.B. – Proctitis/Left colitis[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis – 1st line Vs. O.B. – Proctitis/Left colitis 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis – 2nd line Vs. O.B. – Proctitis/Left colitis 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis Vs. O.B. – Extensive colitis[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 1st line Vs. O.B. – Extensive colitis – 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 2nd line Vs. O.B. – Extensive colitis – 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing n	Patients with one intensification or more n(%)	Total no-missing n	Patients with one intensification or more n(%)	OR (IC95%)*	p-value*
VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

*Estimated with a logistic regression.

[1]Data without PS-IPTW.

[2]Data with PS-IPTW (CD).

[3]Data with PS-IPTW (CD-1st line).

[4]Data with PS-IPTW (CD-2nd line).

[5]Data with PS-IPTW (UC).

[6]Data with PS-IPTW (UC-1st line).

[7]Data with PS-IPTW (UC-2nd line).

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.5.2 CD patients with VDZ – One intensification or more Logistic regression model (p-values)

	n	Missing	p-value
Model	xx	xx	
Line treatment			x.xxxx
Type of diagnosis			x.xxxx
Disease duration			x.xxxx
Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment and Type of diagnosis			x.xxxx
Interaction Line treatment and Disease duration			x.xxxx
Interaction Line treatment and Type of disease behaviour at diagnosis			x.xxxx
Interaction Type of diagnosis and Disease duration			x.xxxx
Interaction Type of diagnosis and Type of disease behaviour at diagnosis			x.xxxx
Interaction Disease duration and Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment, Type of diagnosis and Disease duration			x.xxxx
Interaction Line treatment, Type of diagnosis and Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment, Disease duration and Type of disease behaviour at diagnosis			x.xxxx
Interaction Type of diagnosis, Disease duration and Type of disease behaviour at diagnosis			x.xxxx

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	n	Missing	p-value
Interaction Line treatment, Type of diagnosis, Disease duration and Type of disease behaviour at diagnosis			x.xxxx

Table 4.5.3 CD patients with VDZ – One intensification or more Logistic regression model (estimated OR)

		OR (CI 95%)
Line Treatment	2nd line Vs. 1st line	xx.x (xx.x, xx.x)
Type of diagnosis	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
Line Treatment	2 years or more Vs. less than 2 years	xx.x (xx.x, xx.x)
Type of disease behaviour at diagnosis	Inflammatory Vs. Stricturing / Penetrating	xx.x (xx.x, xx.x)
Interaction Line treatment and Type of diagnosis		
2nd line	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
1st line	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
…		

Note: Only significant variables and/or interactions (Table 4.4.2) will be included in this table.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Table 4.5.4 UC patients with VDZ – One intensification or more Logistic regression model (p-values)

	n	Missing	p-value
Model	xx	xx	
Line treatment			x.xxxx
Type of diagnosis			x.xxxx
Disease duration			x.xxxx
Interaction Line treatment and Type of diagnosis			x.xxxx
Interaction Line treatment and Disease duration			x.xxxx
Interaction Type of diagnosis and Disease duration			x.xxxx
Interaction Line treatment, Type of diagnosis and Disease duration			x.xxxx

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.5.5 UC patients with VDZ – One intensification or more Logistic regression model (estimated OR)

		OR (CI 95%)
Line Treatment	2nd line Vs. 1st line	xx.x (xx.x, xx.x)
Type of diagnosis	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
Line Treatment	2 years or more Vs. less than 2 years	xx.x (xx.x, xx.x)
Interaction Line treatment and Type of diagnosis		
2nd line	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
1st line	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
…		

Note: Only significant variables and/or interactions (Table 4.4.4) will be included in this table.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.5.6 CD patients with Other Biologic – One intensification or more Logistic regression model (p-values)

	n	Missing	p-value
Model	xx	xx	
Line treatment			x.xxxx
Type of diagnosis			x.xxxx
Disease duration			x.xxxx
Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment and Type of diagnosis			x.xxxx
Interaction Line treatment and Disease duration			x.xxxx
Interaction Line treatment and Type of disease behaviour at diagnosis			x.xxxx
Interaction Type of diagnosis and Disease duration			x.xxxx
Interaction Type of diagnosis and Type of disease behaviour at diagnosis			x.xxxx
Interaction Disease duration and Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment, Type of diagnosis and Disease duration			x.xxxx
Interaction Line treatment, Type of diagnosis and Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment, Disease duration and Type of disease behaviour at diagnosis			x.xxxx
Interaction Type of diagnosis, Disease duration and Type of disease behaviour at diagnosis			x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	n	Missing	p-value
Interaction Line treatment, Type of diagnosis, Disease duration and Type of disease behaviour at diagnosis			x.xxxx

Table 4.5.7 CD patients with Other Biologic – One intensification or more Logistic regression model (estimated OR)

		OR (CI 95%)
Line Treatment	2nd line Vs. 1st line	xx.x (xx.x, xx.x)
Type of diagnosis	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
Line Treatment	2 years or more Vs. less than 2 years	xx.x (xx.x, xx.x)
Type of disease behaviour at diagnosis	Inflammatory Vs. Stricturing / Penetrating	xx.x (xx.x, xx.x)
Interaction Line treatment and Type of diagnosis		
2nd line	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
1st line	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
…		

Note: Only significant variables and/or interactions (Table 4.4.2) will be included in this table.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Table 4.5.8 UC patients with Other Biologic – One intensification or more Logistic regression model (p-values)

	n	Missing	p-value
Model	xx	xx	
Line treatment			x.xxxx
Type of diagnosis			x.xxxx
Disease duration			x.xxxx
Interaction Line treatment and Type of diagnosis			x.xxxx
Interaction Line treatment and Disease duration			x.xxxx
Interaction Type of diagnosis and Disease duration			x.xxxx
Interaction Line treatment, Type of diagnosis and Disease duration			x.xxxx

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.5.9 UC patients with Other Biologic – One intensification or more Logistic regression model (estimated OR)

		OR (CI 95%)
Line Treatment	2nd line Vs. 1st line	xx.x (xx.x, xx.x)
Type of diagnosis	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
Line Treatment	2 years or more Vs. less than 2 years	xx.x (xx.x, xx.x)
Interaction Line treatment and Type of diagnosis		
2nd line	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
1st line	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
…		

Note: Only significant variables and/or interactions (Table 4.4.4) will be included in this table.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.4.6 Time to first intensification

Table 4.6.1 Time to first intensification (Months)

	1st group		2nd group		
	Total no-missing* n	Time to first intensification** Median(Q1,Q3)	Total no-missing* n	Time to first intensification** Median(Q1,Q3)	p-value***
CD					
VDZ – 1st line Vs. VDZ – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal Vs. VDZ – Colonic/Ileocolonic[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 1st line Vs. VDZ – Colonic/Ileocolonic – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 2nd line Vs. VDZ – Colonic/Ileocolonic – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory Vs. VDZ – Stricturing/Penetrating[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 1st line Vs. VDZ – Stricturing/Penetrating – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 2nd line Vs. VDZ – Stricturing/Penetrating – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n	Time to first intensification** Median(Q1,Q3)	Total no-missing* n	Time to first intensification** Median(Q1,Q3)	p-value***
O.B. – 1st line Vs. O.B. – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal Vs. O.B. – Colonic/Ileocolonic[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – 1st line Vs. O.B. – Colonic/Ileocolonic – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – 2nd line Vs. O.B. – Colonic/Ileocolonic – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory Vs. O.B. – Stricturing/Penetrating[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Vs. O.B.[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. O.B. 1st line[3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. O.B. 2nd line[4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic Vs. O.B. – Colonic/Ileocolonic[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n	Time to first intensification** Median(Q1,Q3)	Total no-missing* n	Time to first intensification** Median(Q1,Q3)	p-value***
VDZ – Colonic/Ileocolonic – 1st line Vs. O.B. – Colonic/Ileocolonic 1st line[3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic – 2nd line Vs. O.B. – Colonic/Ileocolonic 2nd line[4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal Vs. O.B. – Ileal[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 1st line Vs. O.B. – Ileal – 1st line[3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 2nd line Vs. O.B. – Ileal – 2nd line[4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory Vs. O.B. – Inflamatory[2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n	Time to first intensification** Median(Q1,Q3)	Total no-missing* n	Time to first intensification** Median(Q1,Q3)	p-value***
VDZ – Inflamatory – 1st line Vs. O.B. – Inflamatory – 1st line [3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 2nd line Vs. O.B. – Inflamatory – 2nd line [4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating Vs. O.B. – Stricturing/Penetrating [2]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line [3]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line [4]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
UC					
VDZ – 1st line Vs. VDZ – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis Vs. VDZ – Proctitis/Left colitis[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 1st line Vs. VDZ – Proctitis/Left colitis – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 2nd line Vs. VDZ – Proctitis/Left colitis – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n	Time to first intensification** Median(Q1,Q3)	Total no-missing* n	Time to first intensification** Median(Q1,Q3)	p-value***
VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 1st line Vs. O.B. – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis Vs. O.B. – Proctitis/Left colitis[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – 1st line Vs. O.B. – Proctitis/Left colitis – 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – 2nd line Vs. O.B. – Proctitis/Left colitis – 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ Vs. O.B.[5]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. O.B. 1st line[6]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. O.B. 2nd line[7]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis Vs. O.B. – Proctitis/Left colitis[5]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis – 1st line Vs. O.B. – Proctitis/Left colitis 1st line[6]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group		
	Total no-missing* n	Time to first intensification** Median(Q1,Q3)	Total no-missing* n	Time to first intensification** Median(Q1,Q3)	p-value***
VDZ – Proctitis/Left colitis – 2nd line Vs. O.B. – Proctitis/Left colitis 2nd line[7]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis Vs. O.B. – Extensive colitis[5]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 1st line Vs. O.B. – Extensive colitis – 1st line[6]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 2nd line Vs. O.B. – Extensive colitis – 2nd line[7]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[5]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[6]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[7]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[5]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[6]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[7]	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	x.xxxx

*Patients with correct data to calculate “time to first intensification”.

**Estimated with Kaplan-Meier method.

***Estimated with LogRank test.

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

[1]Data without PS-IPTW.

[2]Data with PS-IPTW (CD).

[3]Data with PS-IPTW (CD-1st line).

[4]Data with PS-IPTW (CD-2nd line).

[5]Data with PS-IPTW (UC).

[6]Data with PS-IPTW (UC-1st line).

[7]Data with PS-IPTW (UC-2nd line).

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.4.7 Clinical response

Table 4.7.1 Clinical response at 14 weeks

	1st group		2nd group			
	Total no-missing	Patients with clinical response	Total no-missing	Patients with clinical response		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
CD						
VDZ – 1st line Vs. VDZ – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal Vs. VDZ – Colonic/Ileocolonic[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 1st line Vs. VDZ – Colonic/Ileocolonic – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 2nd line Vs. VDZ – Colonic/Ileocolonic – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – Intensification Vs. VDZ – Colonic/Ileocolonic – Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – No Intensification Vs. VDZ – Colonic/Ileocolonic – No Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with clinical response	Total no-missing	Patients with clinical response		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory Vs. VDZ – Stricturing/Penetrating[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 1st line Vs. VDZ – Stricturing/Penetrating – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 2nd line Vs. VDZ – Stricturing/Penetrating – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 1st line Vs. O.B. – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal Vs. O.B. – Colonic/Ileocolonic[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – 1st line Vs. O.B. – Colonic/Ileocolonic – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – 2nd line Vs. O.B. – Colonic/Ileocolonic – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – Intensification Vs. O.B. – Colonic/Ileocolonic – Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Ileal – No Intensification Vs. O.B. – Colonic/Ileocolonic – No Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with clinical response	Total no-missing	Patients with clinical response		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory Vs. O.B. – Stricturing/Penetrating[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Inflamatory – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Vs. O.B.[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. O.B. 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. O.B. 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic Vs. O.B. – Colonic/Ileocolonic[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic – 1st line Vs. O.B. – Colonic/Ileocolonic 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Colonic/Ileocolonic – 2nd line Vs. O.B. – Colonic/Ileocolonic 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with clinical response	Total no-missing	Patients with clinical response		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
VDZ – Ileal Vs. O.B. – Ileal[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 1st line Vs. O.B. – Ileal – 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Ileal – 2nd line Vs. O.B. – Ileal – 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory Vs. O.B. – Inflamatory[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with clinical response	Total no-missing	Patients with clinical response		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
VDZ – Inflamatory – 1st line Vs. O.B. – Inflamatory – 1st line [3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Inflamatory – 2nd line Vs. O.B. – Inflamatory – 2nd line [4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating Vs. O.B. – Stricturing/Penetrating [2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating – 1st line Vs. O.B. – Stricturing/Penetrating – 1st line [3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Stricturing/Penetrating – 2nd line Vs. O.B. – Stricturing/Penetrating – 2nd line [4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
UC						
VDZ – 1st line Vs. VDZ – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis Vs. VDZ – Proctitis/Left colitis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 1st line Vs. VDZ – Proctitis/Left colitis – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 2nd line Vs. VDZ – Proctitis/Left colitis – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – Intensification Vs. VDZ – Proctitis/Left colitis – Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with clinical response	Total no-missing	Patients with clinical response		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
VDZ – Extensive colitis – No Intensification Vs. VDZ – Proctitis/Left colitis – No Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis Vs. VDZ – less than 2 years diagnosis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 1st line Vs. VDZ – less than 2 years diagnosis – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2 years or more diagnosis – 2nd line Vs. VDZ – less than 2 years diagnosis – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 1st line Vs. O.B. – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis Vs. O.B. – Proctitis/Left colitis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – 1st line Vs. O.B. – Proctitis/Left colitis – 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – 2nd line Vs. O.B. – Proctitis/Left colitis – 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – Extensive colitis – Intensification Vs. O.B. – Proctitis/Left colitis – Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with clinical response	Total no-missing	Patients with clinical response		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
O.B. – Extensive colitis – No Intensification Vs. O.B. – Proctitis/Left colitis – No Intesification[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis Vs. O.B. – less than 2 years diagnosis[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis 1st line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
O.B. – 2 years or more diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis 2nd line[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ Vs. O.B.[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. O.B. 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. O.B. 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis Vs. O.B. – Proctitis/Left colitis[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis – 1st line Vs. O.B. – Proctitis/Left colitis 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Proctitis/Left colitis – 2nd line Vs. O.B. – Proctitis/Left colitis 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	1st group		2nd group			
	Total no-missing	Patients with clinical response	Total no-missing	Patients with clinical response		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
VDZ – Extensive colitis Vs. O.B. – Extensive colitis[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 1st line Vs. O.B. – Extensive colitis – 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – Extensive colitis – 2nd line Vs. O.B. – Extensive colitis – 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis Vs. O.B. – less than 2 years diagnosis[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 1st line Vs. O.B. – less than 2 years diagnosis – 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – less than 2 years diagnosis – 2nd line Vs. O.B. – less than 2 years diagnosis – 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis Vs. O.B. – 2 years or more diagnosis[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 1st line Vs. O.B. – 2 years or more diagnosis – 1st line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ - 2 years or more diagnosis – 2nd line Vs. O.B. – 2 years or more diagnosis – 2nd line[7]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

*Estimated with a logistic regression.

[1]Data without PS-IPTW.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

[2]Data with PS-IPTW (CD).

[3]Data with PS-IPTW (CD-1st line).

[4]Data with PS-IPTW (CD-2nd line).

[5]Data with PS-IPTW (UC).

[6]Data with PS-IPTW (UC-1st line).

[7]Data with PS-IPTW (UC-2nd line).

Table 4.7.2 Clinical response at 52 weeks

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.7.3 CD patients with VDZ – Clinical response at 52 weeks Logistic regression model (p-values)

	n	Missing	p-value
Model	xx	xx	
Line treatment			x.xxxx
Type of diagnosis			x.xxxx
Disease duration			x.xxxx
Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment and Type of diagnosis			x.xxxx
Interaction Line treatment and Disease duration			x.xxxx
Interaction Line treatment and Type of disease behaviour at diagnosis			x.xxxx
Interaction Type of diagnosis and Disease duration			x.xxxx
Interaction Type of diagnosis and Type of disease behaviour at diagnosis			x.xxxx
Interaction Disease duration and Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment, Type of diagnosis and Disease duration			x.xxxx
Interaction Line treatment, Type of diagnosis and Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment, Disease duration and Type of disease behaviour at diagnosis			x.xxxx
Interaction Type of diagnosis, Disease duration and Type of disease behaviour at diagnosis			x.xxxx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	n	Missing	p-value
Interaction Line treatment, Type of diagnosis, Disease duration and Type of disease behaviour at diagnosis			x.xxxx

Table 4.7.4 CD patients with VDZ – Clinical response at 52 weeks Logistic regression model (estimated OR)

		OR (CI 95%)
Line Treatment	2nd line Vs. 1st line	xx.x (xx.x, xx.x)
Type of diagnosis	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
Line Treatment	2 years or more Vs. less than 2 years	xx.x (xx.x, xx.x)
Type of disease behaviour at diagnosis	Inflammatory Vs. Stricturing / Penetrating	xx.x (xx.x, xx.x)
Interaction Line treatment and Type of diagnosis		
2nd line	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
1st line	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
…		

Note: Only significant variables and/or interactions (Table 4.6.5) will be included in this table.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Table 4.7.5 UC patients with VDZ – Clinical response at 52 weeks Logistic regression model (p-values)

	n	Missing	p-value
Model	xx	xx	
Line treatment			x.xxxx
Type of diagnosis			x.xxxx
Disease duration			x.xxxx
Interaction Line treatment and Type of diagnosis			x.xxxx
Interaction Line treatment and Disease duration			x.xxxx
Interaction Type of diagnosis and Disease duration			x.xxxx
Interaction Line treatment, Type of diagnosis and Disease duration			x.xxxx

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.7.6 UC patients with VDZ – Clinical response at 52 weeks Logistic regression model (estimated OR)

		OR (CI 95%)
Line Treatment	2nd line Vs. 1st line	xx.x (xx.x, xx.x)
Type of diagnosis	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
Line Treatment	2 years or more Vs. less than 2 years	xx.x (xx.x, xx.x)
Interaction Line treatment and Type of diagnosis		
2nd line	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
1st line	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
…		

Note: Only significant variables and/or interactions (Table 4.6.7) will be included in this table.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.7.7 CD patients with Other Biologic – Clinical response at 52 weeks Logistic regression model (p-values)

	n	Missing	p-value
Model	xx	xx	
Line treatment			x.xxxx
Type of diagnosis			x.xxxx
Disease duration			x.xxxx
Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment and Type of diagnosis			x.xxxx
Interaction Line treatment and Disease duration			x.xxxx
Interaction Line treatment and Type of disease behaviour at diagnosis			x.xxxx
Interaction Type of diagnosis and Disease duration			x.xxxx
Interaction Type of diagnosis and Type of disease behaviour at diagnosis			x.xxxx
Interaction Disease duration and Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment, Type of diagnosis and Disease duration			x.xxxx
Interaction Line treatment, Type of diagnosis and Type of disease behaviour at diagnosis			x.xxxx
Interaction Line treatment, Disease duration and Type of disease behaviour at diagnosis			x.xxxx
Interaction Type of diagnosis, Disease duration and Type of disease behaviour at diagnosis			x.xxxx

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	n	Missing	p-value
Interaction Line treatment, Type of diagnosis, Disease duration and Type of disease behaviour at diagnosis			x.xxxx

Table 4.7.8 CD patients with Other Biologic – Clinical response at 52 weeks Logistic regression model (estimated OR)

		OR (CI 95%)
Line Treatment	2nd line Vs. 1st line	xx.x (xx.x, xx.x)
Type of diagnosis	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
Line Treatment	2 years or more Vs. less than 2 years	xx.x (xx.x, xx.x)
Type of disease behaviour at diagnosis	Inflammatory Vs. Stricturing / Penetrating	xx.x (xx.x, xx.x)
Interaction Line treatment and Type of diagnosis		
2nd line	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
1st line	Ileal Vs. Colonic/Ileocolonic	xx.x (xx.x, xx.x)
…		

Note: Only significant variables and/or interactions (Table 4.6.5) will be included in this table.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Table 4.7.9 UC patients with Other Biologic – Clinical response at 52 weeks Logistic regression model (p-values)

	n	Missing	p-value
Model	xx	xx	
Line treatment			x.xxxx
Type of diagnosis			x.xxxx
Disease duration			x.xxxx
Interaction Line treatment and Type of diagnosis			x.xxxx
Interaction Line treatment and Disease duration			x.xxxx
Interaction Type of diagnosis and Disease duration			x.xxxx
Interaction Line treatment, Type of diagnosis and Disease duration			x.xxxx

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 4.7.10 UC patients with Other Biologic – Clinical response at 52 weeks Logistic regression model (estimated OR)

		OR (CI 95%)
Line Treatment	2nd line Vs. 1st line	xx.x (xx.x, xx.x)
Type of diagnosis	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
Line Treatment	2 years or more Vs. less than 2 years	xx.x (xx.x, xx.x)
Interaction Line treatment and Type of diagnosis		
2nd line	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
1st line	Extensive colitis Vs. Proctitis/Left colitis	xx.x (xx.x, xx.x)
…		

Note: Only significant variables and/or interactions (Table 4.6.7) will be included in this table.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.4.8 Clinical remission

Table 4.8.1 Clinical remission at 14 weeks

Table 4.8.2 Clinical remission at 52 weeks

Table 4.8.3 CD patients with VDZ – Clinical remission at 52 weeks Logistic regression model (p-values)

Table 4.8.4 CD patients with VDZ – Clinical remission at 52 weeks Logistic regression model (estimated OR)

Table 4.8.5 UC patients with VDZ – Clinical remission at 52 weeks Logistic regression model (p-values)

Table 4.8.6 UC patients with VDZ – Clinical remission at 52 weeks Logistic regression model (estimated OR)

Table 4.8.7 CD patients with Other Biologic – Clinical remission at 52 weeks Logistic regression model (p-values)

Table 4.8.8 CD patients with Other Biologic – Clinical remission at 52 weeks Logistic regression model (estimated OR)

Table 4.8.9 UC patients with Other Biologic – Clinical remission at 52 weeks Logistic regression model (p-values)

Table 4.8.10UC patients with Other Biologic – Clinical remission at 52 weeks Logistic regression model (estimated OR)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.4.9 Endoscopic response at 52 weeks

Table 4.9.1 Endoscopic response at 52 weeks

Table 4.9.2 CD patients with VDZ – Endoscopic response at 52 weeks Logistic regression model (p-values)

Table 4.9.3 CD patients with VDZ – Endoscopic response at 52 weeks Logistic regression model (estimated OR)

Table 4.9.4 UC patients with VDZ – Endoscopic response at 52 weeks Logistic regression model (p-values)

Table 4.9.5 UC patients with VDZ – Endoscopic response at 52 weeks Logistic regression model (estimated OR)

Table 4.9.6 CD patients with Other Biologic – Endoscopic response at 52 weeks Logistic regression model (p-values)

Table 4.9.7 CD patients with Other Biologic – Endoscopic response at 52 weeks Logistic regression model (estimated OR)

Table 4.9.8 UC patients with Other Biologic – Endoscopic response at 52 weeks Logistic regression model (p-values)

Table 4.9.9 UC patients with Other Biologic – Endoscopic response at 52 weeks Logistic regression model (estimated OR)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.4.10 Endoscopic remission at 52 weeks

Table 4.10.1Endoscopic remission at 52 weeks

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.4.11 Biochemical remission based on CRP

Table 4.11.1Biochemical remission based on CRP at 14 weeks

Table 4.11.2Biochemical remission based on CRP at 52 weeks

9.4.12 Biochemical remission based on fecal calprotectin

Table 4.12.1Biochemical remission based on fecal calprotectin at 14 weeks

Table 4.12.2Biochemical remission based on fecal calprotectin at 52 weeks

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.5 Secondary objectives

9.5.1 Describe the real world clinical effectiveness of VDZ vs. other biologics at least 12 months post-treatment initiation (in a subgroup of patients with adequate follow-up available)

Included in section 9.4.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.5.2 Quantify healthcare resource utilization including the rates of healthcare professional (HCP) and emergency department (ED) visits, hospitalizations and Inflammatory Bowel Disease (IBD) related surgical procedures

Table 5.2.1 Health resource utilization – CD with VDZ patients

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
Any visit?			
Total no-missing	n	xx	xx
No	n (%)	xx (xx.x%)	xx (xx.x%)
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Visit of:*			
Total no-missing	n	xx	xx
Emergency doctor	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Specialist	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Surgery	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Diagnostic test	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Hospital admission	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Hospital admission (without surgery)	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Visit with professional:*			
Total no-missing	n	xx	xx
Internist	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
General Practitioner	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
…			

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
Visit with surgery:*			
Total no-missing	n	xx	xx
Resection	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Resection with ostomy	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
…			
Visit with diagnostic test:*			
Total no-missing	n	xx	xx
Endoscopy	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
MRI	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
…			
Any visit with hospitalization?			
Total no-missing	n	xx	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Number of hospitalization days	n[1]	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx

[1]Number of visits.

Table 5.2.2 Health resource utilization related to the pathology – CD with VDZ patients

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
Any visit?			
Total no-missing	n	xx	xx
No	n (%)	xx (xx.x%)	xx (xx.x%)
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

Visit of:*

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
Total no-missing	n	xx	xx
Emergency doctor	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Specialist	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Surgery	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Diagnostic test	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Hospital admission	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Hospital admission (without surgery)	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
Visit with professional:*			
Total no-missing	n	xx	xx
Internist	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
General Practitioner	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
…			
Visit with surgery:*			
Total no-missing	n	xx	xx
Resection	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Resection with ostomy	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
…			
Visit with diagnostic test:*			
Total no-missing	n	xx	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
Endoscopy	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
MRI	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
…			
Any visit with hospitalization?			
Total no-missing	n	xx	xx
No	n (%)	xx (xx.x%)	xx (xx.x%)
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Number of hospitalization days	n[1]	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx

[1]Number of visits.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.2.3 Health resource utilization – CD patients with other biologic

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
Any visit?			
Total no-missing	n	xx	xx
No	n (%)	xx (xx.x%)	xx (xx.x%)
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Visit of:*			
Total no-missing	n	xx	xx
Emergency doctor	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Specialist	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Surgery	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Diagnostic test	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Hospital admission	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Hospital admission (without surgery)	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Visit with professional:*			
Total no-missing	n	xx	xx
Internist	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
General Practitioner	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
…			
Visit with surgery:*			
Total no-missing	n	xx	xx

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
Resection	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Resection with ostomy	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
…			
Visit with diagnostic test:*			
Total no-missing	n	xx	xx
Endoscopy	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
MRI	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
…			
Any visit with hospitalization?			
Total no-missing	n	xx	xx
No	n (%)	xx (xx.x%)	xx (xx.x%)
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Number of hospitalization days	n[1]	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx

[1]Number of visits.

Table 5.2.4 Health resource utilization related to the pathology – CD patients with other biologic

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
Any visit?			
Total no-missing	n	xx	xx
No	n (%)	xx (xx.x%)	xx (xx.x%)
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Visit of:*			
Total no-missing	n	xx	xx
Emergency doctor	n (%)	xx (xx.x%)	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Specialist	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Surgery	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Diagnostic test	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Hospital admission	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Hospital admission (without surgery)	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

Visit with professional:*

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
Total no-missing	n	xx	xx
Internist	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
General Practitioner	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
…			
Visit with surgery:*			
Total no-missing	n	xx	xx
Resection	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Resection with ostomy	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
…			
Visit with diagnostic test:*			
Total no-missing	n	xx	xx
Endoscopy	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

		12 months pre -Index date and index date (n=xx)	12 months Post-Index date (n=xx)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
MRI	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
…			
Any visit with hospitalization?			
Total no-missing	n	xx	xx
No	n (%)	xx (xx.x%)	xx (xx.x%)
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
1	n (%)	xx (xx.x%)	xx (xx.x%)
2	n (%)	xx (xx.x%)	xx (xx.x%)
…	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Number of hospitalization days	n[1]	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx

[1]Number of visits.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.2.1 Health resource utilization – UC patients with VDZ

Table 5.2.2 Health resource utilization related to the pathology – UC patients with VDZ

Table 5.2.3 Health resource utilization – CD patients with other biologic

Table 5.2.4 Health resource utilization related to the pathology – UC patients with other biologic

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.5.3 Identify predictors of response to VDZ

Included in section 9.4.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.5.4 Describe treatment patterns, clinical effectiveness and safety events for at least the induction phase of the subsequent biologic regimen for patients who discontinue index treatment in the VDZ cohort and initiate a second -line biologic within 6 months post-index treatment discontinuation

Table 5.4.1 Patients who discontinue index treatment in the VDZ cohort and initiate a second-line biologic within 6 months post-index treatment discontinuation

		VDZ (CD) (n=xx)	VDZ (UC) (n=xx)
Patients with treatment discontinuation			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Patients who initiate a new-line biologic within 6 months post-index treatment discontinuation[1]			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

[1]Patients with treatment discontinuation.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.4.1 New treatment

		VDZ with new treatment within 6 months post-index treatment discontinuation (CD) (n=xx)	VDZ with new treatment within 6 months post-index treatment discontinuation (UC) (n=xx)
Time from index date to new treatment (months)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Time from treatment discontinuation to new treatment (months)	n	xx	xx
	Mean (SD)	xx.x (xx.x)	xx.x (xx.x)
	Median (Q1, Q3)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
	Min, Max	xx, xx	xx, xx
	Missing	xx	xx
Patients with treatment discontinuation			
Total no-missing	n	xx	xx
Golimumab	n (%)	xx (xx.x%)	xx (xx.x%)
Ceertolizumab	n (%)	xx (xx.x%)	xx (xx.x%)
Infliximab	n (%)	xx (xx.x%)	xx (xx.x%)
Ustekinumab	n (%)	xx (xx.x%)	xx (xx.x%)
Tofacitinib	n (%)	xx (xx.x%)	xx (xx.x%)
Adalimumab	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

[1]Patients with treatment discontinuation

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.4.2 Posology (mg) by treatment

	n	Media (Desv. estándar)	Mediana (Q1, Q3)	Min, Max	Missing
CD					
Golimumab	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Ceertolizumab	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Infliximab	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Ustekinumab	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Tofacitinib	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Adalimumab	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
UC					
Golimumab	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Ceertolizumab	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Infliximab	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Ustekinumab	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Tofacitinib	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx
Adalimumab	xx	xx.x (xx.x)	xx.x (xx.x, xx.x)	xx, xx	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.4.1 New treatment – Response and remission 14 weeks

		VDZ with new treatment within 6 months post-index treatment discontinuation (CD) (n=xx)	VDZ with new treatment within 6 months post-index treatment discontinuation (UC) (n=xx)
Response at 14 weeks			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx
Remission at 14 weeks			
Total no-missing	n	xx	xx
Yes	n (%)	xx (xx.x%)	xx (xx.x%)
No	n (%)	xx (xx.x%)	xx (xx.x%)
Missing	n	xx	xx

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.4.2 New treatment – Adverse Events

	VDZ with new treatment within 6 months post-index treatment discontinuation (CD) (n=xx)		VDZ with new treatment within 6 months post-index treatment discontinuation (UC) (n=xx)	
	Total no-missing	Patients with any AE	Total no-missing	Patients with any AE
	n	n(%)	n	n(%)
Adverse event	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event r	xx	xx (xx.x%)	xx	xx (xx.x%)
Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Infections, serious infections and malignancies	xx	xx (xx.x%)	xx	xx (xx.x%)

Note: Adverse Events since start of new treatment.

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

9.5.5 Describe the safety events occurring post biologic treatment initiation (VDZ or other biologics)

Table 5.5.1 Adverse Events

	VDZ		Other Biologic	
	Total no-missing	Patients with any AE	Total no-missing	Patients with any AE
	n	n(%)	n	n(%)
CD				
Adverse event	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event r	xx	xx (xx.x%)	xx	xx (xx.x%)
Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Infections, serious infections and malignancies	xx	xx (xx.x%)	xx	xx (xx.x%)
CD 1st line				
Adverse event	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event r	xx	xx (xx.x%)	xx	xx (xx.x%)
Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Infections, serious infections and malignancies	xx	xx (xx.x%)	xx	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	VDZ		Other Biologic	
	Total no-missing	Patients with any AE	Total no-missing	Patients with any AE
	n	n(%)	n	n(%)
CD 2nd line				
Adverse event	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event r	xx	xx (xx.x%)	xx	xx (xx.x%)
Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Infections, serious infections and malignancies	xx	xx (xx.x%)	xx	xx (xx.x%)
UC				
Adverse event	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event r	xx	xx (xx.x%)	xx	xx (xx.x%)
Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Infections, serious infections and malignancies	xx	xx (xx.x%)	xx	xx (xx.x%)
UC 1st line				
Adverse event	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event r	xx	xx (xx.x%)	xx	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

	VDZ		Other Biologic	
	Total no-missing	Patients with any AE	Total no-missing	Patients with any AE
	n	n(%)	n	n(%)
Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Infections, serious infections and malignancies	xx	xx (xx.x%)	xx	xx (xx.x%)
UC 2nd line				
Adverse event	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event r	xx	xx (xx.x%)	xx	xx (xx.x%)
Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Serious Adverse event related with treatment	xx	xx (xx.x%)	xx	xx (xx.x%)
Infections, serious infections and malignancies	xx	xx (xx.x%)	xx	xx (xx.x%)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda. For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Table 5.5.2 Adverse event (incidence)

	1st group		2nd group			
	Total no-missing	Patients with any AE	Total no-missing	Patients with any AE		
	n	n(%)	n	n(%)	OR (IC95%)*	p-value*
CD						
VDZ Vs. Other Biologic[1]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. Other Biologic 1st line[2]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. Other Biologic 2nd line[3]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
UC						
VDZ Vs. Other Biologic[4]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 1st line Vs. Other Biologic 1st line[5]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx
VDZ – 2nd line Vs. Other Biologic 2nd line[6]	xx	xx (xx.x%)	xx	xx (xx.x%)	xx.x (xx.x, xx.x)	x.xxxx

*Estimated with a logistic regression.

[1]Data with PS-IPTW (CD); [2]Data with PS-IPTW (CD-1st line); [3]Data with PS-IPTW (CD-2nd line)

[4]Data with PS-IPTW (UC); [5]Data with PS-IPTW (UC-1st line); [6]Data with PS-IPTW (UC-2nd line)

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.5.3 Serious Adverse event (incidence)

Table 5.5.4 Related with treatmetn Adverse Event (incidence)

Table 5.5.5 Related with treatment Serious Adverse Event (incidence)

Table 5.5.6 Adverse event - Infections, serious infections and malignancies (incidence)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Table 5.5.1 Adverse event (incidence rate)

	1st group		2nd group			
	Total no-missing	Nº AEs	Total no-missing	Nº AEs		
	n	100 patient/year	n	100 patient/year	RR (IC95%)*	p-value*
CD						
VDZ Vs. Other Biologic[1]	xx	x.xx	xx	xx (xx.x%)	x.xx	x.xxxx
VDZ – 1st line Vs. Other Biologic 1st line[1]	xx	x.xx	xx	xx (xx.x%)	x.xx	x.xxxx
VDZ – 2nd line Vs. Other Biologic 2nd line[2]	xx	x.xx	xx	xx (xx.x%)	x.xx	x.xxxx
UC						
VDZ Vs. Other Biologic[3]	xx	x.xx	xx	xx (xx.x%)	x.xx	x.xxxx
VDZ – 1st line Vs. Other Biologic 1st line[3]	xx	x.xx	xx	xx (xx.x%)	x.xx	x.xxxx
VDZ – 2nd line Vs. Other Biologic 2nd line[4]	xx	x.xx	xx	xx (xx.x%)	x.xx	x.xxxx

*Estimated with a Poisson regression including the following time.

[1]Data with PS-IPTW (CD); [2]Data with PS-IPTW (CD-1st line); [3]Data with PS-IPTW (CD-2nd line)

[4]Data with PS-IPTW (UC); [5]Data with PS-IPTW (UC-1st line); [6]Data with PS-IPTW (UC-2nd line)

Table 5.5.2 Serious Adverse event (incidence rate)

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.5.3 Related with index date Adverse Event (incidence rate)

Table 5.5.4 Related with index date Serious Adverse Event (incidence rate)

Table 5.5.5 Adverse event - Infections, serious infections and malignancies (incidence rate)

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.5.6 Adverse Events I – CD patients with VDZ

			Resolved					AE seriousness criteria assessment Causality/Relationship to study drug					
	Nº pat. (%)	Nº AE	Yes	No	Unkn.	Duration (days)*	Death	Life-threating	Hosp. or prolong. Hosp.	Disability/ incapacity	Congenital anomaly/birth defect	Important medical event	None
Overall	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
SOC 1	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
PT 1	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
PT 2	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
…													
SOC 2	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
PT 1	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
PT 2	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
…													
…													

*Mean (Standard Deviation).

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.5.7 Adverse Events II – CD patients with VDZ

			Related to index drug		Action taken with VDZ						
	Nº pat. (%)	Nº AE	Yes	No	Trt. Withdrawn	Dose reduced	Dose increased	Dose delayed	Dose not changed	Unknown	Not applicable
Overall	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
SOC 1	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
PT 1	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
PT 2	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
…											
SOC 2	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
PT 1	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
PT 2	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
…											
…											

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.5.8 Adverse Events III – CD patients with VDZ

			Outcome					
	Nº pat. (%)	Nº AE	Recovered	Recovering	Not recovered	Recovered with sequelae	Fatal	Unknown
Overall	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
SOC 1	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
PT 1	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
PT 2	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
…								
SOC 2	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
PT 1	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
PT 2	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
…								
…								

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.5.9 Adverse Events I – CD patients with Other Biologic

			Resolved				AE seriousness criteria assessment Causality/Relationship to study drug						
	Nº pat. (%)	Nº AE	Yes	No	Unkn.	Duration (days)*	Death	Life-threating	Hosp. or prolong. Hosp.	Disability/ incapacity	Congenital anomaly/birth defect	Important medical event	None
Overall	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
SOC 1	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
PT 1	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
PT 2	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
…													
SOC 2	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
PT 1	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
PT 2	xx (xx.x)	xx	xx	xx	xx	x.x (x.x)	xx	xx	xx	xx	xx	xx	xx
…													
…													

*Mean (Standard Deviation).

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

Table 5.5.10Adverse Events II – CD patients with Other Biologic

			Related to index drug		Action taken with Other Biologic						
	Nº pat. (%)	Nº AE	Yes	No	Trt. Withdrawn	Dose reduced	Dose increased	Dose delayed	Dose not changed	Unknown	Not applicable
Overall	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
SOC 1	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
PT 1	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
PT 2	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
…											
SOC 2	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
PT 1	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
PT 2	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
…											
…											

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.5.11Adverse Events III – CD patients with Other Biologic

			Outcome					
	Nº pat. (%)	Nº AE	Recovered	Recovering	Not recovered	Recovered with sequelae	Fatal	Unknown
Overall	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
SOC 1	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
PT 1	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
PT 2	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
…								
SOC 2	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
PT 1	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
PT 2	xx (xx.x)	xx	xx	xx	xx	xx	xx	xx
…								
…								

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.

DocuSign Envelope ID: CA40325A-D71D-440F-B9FA-A1B667CD9B61

Table 5.5.12Adverse Events I – UC patients with VDZ

Table 5.5.13Adverse Events II – UC patients with VDZ

Table 5.5.14Adverse Events III – UC patients with VDZ

Table 5.5.15Adverse Events I – UC patients with Other Biologic

Table 5.5.16Adverse Events II – UC patients with Other Biologic

Table 5.5.17Adverse Events III – UC patients with Other Biologic

Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use

All rights reserved. No part of this material may be reproduced or copied in any form by any means (written, electronic, photocopying, recording or otherwise) without the prior consent of BioClever.